Cancer treatment method using anti-CTLA4 antibody

Abstract

The present application provides compositions and methods for treating cancer, including cancers that are resistant or refractory to inhibitors of PD-1 or PD-L1, using anti-CTLA4 antibodies, including combination therapies.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 402,247, filed August 30, 2022, the disclosure of which is incorporated herein by reference in its entirety.

[0002] Reference to Electronic Sequence Listing The contents of the electronic sequence listing (695402002540SEQLIST.xml, size: 187,921 bytes, creation date: August 24, 2023) are incorporated herein by reference in their entirety.

[0003] This application is in the field of cancer treatment and relates to compositions and methods for treating cancer using antibodies that bind to human CTLA4. [Background technology]

[0004] CTLA4 is a member of the immunoglobulin (Ig) superfamily of proteins that downregulates T cell activation and maintains immunogenic homeostasis. In vivo antibody-mediated blockade of CTLA4 has been shown to enhance anti-cancer immune responses in a syngeneic mouse prostate cancer model (Kwon et al. (1997) Proc Natl Acad Sci USA, 94(15):8099-103). Furthermore, blockade of CTLA4 function has been shown to enhance anti-tumor T cell responses at various stages of tumor growth in tumor-bearing mice (Yang et al. (1997) Cancer Res 57(18):4036-41; Hurwitz et al. (1998) Proc Natl Acad Sci USA 95(17):10067-7). However, the development of antibody-based therapeutics suitable for human use remains challenging because translation from preclinical animal models to human safety is often insufficient. Therefore, there is a need for anti-CTLA4 antibodies that are cross-reactive between different species, such as humans and experimental animals (e.g., mice, monkeys, rats, etc.), to enable animal model studies while also providing suitable human therapeutic candidates. Furthermore, there is a need for the development of safer anti-CTLA4 antibodies that are active only in specific contexts, such as the protease-rich tumor microenvironment. Summary of the Invention

[0005] The present application provides methods for treating cancer with anti-CTLA4 antibodies, which specifically bind to an epitope of human CTLA4 that includes amino acid residues Y105 and L106, but not residue 1108. The present application also provides methods for treating cancer using the anti-CTLA4 antibodies of the present disclosure in combination with one or more therapeutic agents, particularly anti-PD-1 antibodies.

[0006] In some embodiments according to any one of the above methods, the antibody is a human antibody. In some embodiments, the antibody comprises an IgG1, IgG2, IgG3, or IgG4 Fc region (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc region). In some embodiments, the antibody comprises a human IgG1 or variant with enhanced ADCC activity. In some embodiments, the antibody comprises a human IgG1 with reduced fucosylation (or no fucosylation).

[0007] In some embodiments, the anti-CTLA4 antibody comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, and the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, wherein HVR-H1 comprises an amino acid sequence according to the formula YSISSGYHWSWI (SEQ ID NO: 23), HVR-H2 comprises an amino acid sequence according to the formula LARIDWDDDKYYSTSLKSRL (SEQ ID NO: 35), HVR-H3 comprises an amino acid sequence according to the formula ARSYVYFDY (SEQ ID NO: 45), HVR-L1 comprises an amino acid sequence according to the formula RASQSVRGRFLA (SEQ ID NO: 58), HVR-L2 comprises an amino acid sequence according to the formula DASNRATGI (SEQ ID NO: 66), and HVR-L3 comprises an amino acid sequence according to the formula YCQQSSSWPPT (SEQ ID NO: 75).

[0008] In some embodiments, the anti-CTLA4 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87, or a variant thereof having at least about 90% (e.g., at least about 92%, 95%, 98%, 99% or more) sequence identity to the amino acid sequence of SEQ ID NO: 87, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 100, or a variant thereof having at least about 90% (e.g., at least about 92%, 95%, 98%, 99% or more) sequence identity to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the anti-CTLA4 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100.

[0009] In some embodiments, the anti-CTLA4 antibody is EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICN VNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF a heavy chain region comprising the amino acid sequence of SCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 126) or a variant thereof having at least about 90% (e.g., at least about 92%, 95%, 98%, 99% or more) sequence identity to the amino acid sequence of SEQ ID NO: 126, and and a heavy chain region comprising the amino acid sequence of SEQ ID NO: 126, SEQ ID NO: 127, or a variant thereof having at least about 90% (e.g., at least about 92%, 95%, 98%, 99% or more) sequence identity to the amino acid sequence of SEQ ID NO: 127. In some embodiments, the anti-CTLA4 antibody is TY21580, which comprises a heavy chain region comprising the amino acid sequence of SEQ ID NO: 126, and a light chain region comprising the amino acid sequence of SEQ ID NO: 127.

[0010] In one aspect, the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject as monotherapy an effective amount of the anti-CTLA4 (e.g., TY21580) at a dose of about 3 mg / kg to about 15 mg / kg. In some embodiments, the anti-CTLA4 (e.g., TY21580) is administered at a dose of about 3 mg / kg. In some embodiments, the anti-CTLA4 (e.g., TY21580) is administered at a dose of about 5 mg / kg. In some embodiments, the anti-CTLA4 (e.g., TY21580) is administered at a dose of about 6 mg / kg. In some embodiments, the anti-CTLA4 (e.g., TY21580) is administered at a dose of about 8 mg / kg. In some embodiments, the anti-CTLA4 (e.g., TY21580) is administered at a dose of about 10 mg / kg. In some embodiments, the anti-CTLA4 (e.g., TY21580) is administered at a dose of about 15 mg / kg.

[0011] In another aspect, the present disclosure provides a method of treating cancer in a subject, the method comprising administering to the subject (a) an effective amount of an anti-CTLA4 antibody (e.g., TY21580) described above, and (b) an effective amount of an anti-PD-1 antibody. In one embodiment, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. The antibody can be administered to the subject at a dose of about 1 mg / kg to about 10 mg / kg or about 2 mg / kg to about 5 mg / kg. In some embodiments, the anti-CTLA4 antibody can be administered to the subject at a dose of about 3 mg / kg. In some embodiments, the anti-CTLA4 antibody can be administered to the subject once every three weeks. In other embodiments, the anti-CTLA4 antibody can be administered to the subject once every six weeks. In a specific embodiment, antibody TY21580 can be administered to the patient at a dose of about 3 mg / kg once every three weeks or once every six weeks.

[0012] In some embodiments according to any one of the above methods, the cancer is resistant or refractory to conventional therapy, and the conventional therapy is an inhibitor of CTLA4, PD-1, or PD-1 ligand. In some embodiments, the subject is resistant to or has relapsed from conventional therapy, and the conventional therapy is an inhibitor of CTLA4, PD-1, or PD-1 ligand. In some embodiments, the conventional therapy is an inhibitor of CTLA4, such as ipilimumab. In some embodiments, the conventional therapy is an inhibitor of PD-1, e.g., an anti-PD-1 antibody. In some embodiments, the conventional therapy is an inhibitor of PD-1 ligand (e.g., PD-L1), e.g., an anti-PD-L1 antibody.

[0013] Another aspect of the present application provides a method of treating cancer in a subject, comprising administering to the subject an effective amount of an anti-CTLA4 antibody described above in combination with an anti-PD-1 antibody, where the amino acid residue numbering is based on SEQ ID NO: 108, wherein the cancer is resistant or refractory to conventional treatment, and the conventional treatment is an inhibitor of CTLA4, PD-1, or PD-1 ligand. In some embodiments, the anti-CTLA4 antibody is TY21580.

[0014] In some embodiments according to any one of the above methods, the cancer is liver cancer, cancer of the digestive system (e.g., colon cancer, colorectal cancer), lung cancer, bone cancer, heart cancer, brain cancer, kidney cancer, bladder cancer, blood cancer (e.g., leukemia), skin cancer, breast cancer, thyroid cancer, pancreatic cancer, head and neck cancer, eye-related cancer, cancer of the male reproductive system (e.g., prostate cancer, testicular cancer), or cancer of the female reproductive system (e.g., uterine cancer, cervical cancer). In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is urothelial carcinoma. In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the cancer is pancreatic cancer. In some embodiments, the cancer is advanced stage cancer. In some embodiments, the cancer is metastatic cancer. In some embodiments, the cancer is Kaposi's sarcoma. In some embodiments, the cancer is head and neck squamous cell carcinoma (HNSCC).

[0015] In some embodiments, the anti-CTLA4 antibody is administered intravenously. In some embodiments, the anti-CTLA4 antibody is administered subcutaneously. In some embodiments, the anti-CTLA4 antibody is administered intravenously or subcutaneously once every three weeks. In some embodiments, the anti-CTLA4 antibody is administered intravenously or subcutaneously once every six weeks. In some embodiments, the subject receives at least four cycles of anti-CTLA4 antibody treatment. In some embodiments, the subject further receives maintenance therapy comprising administering to the subject an effective amount of an anti-CTLA4 antibody about once every four weeks to about once every 12 weeks (e.g., once every 4 weeks, 6 weeks, 8 weeks, 10 weeks, or 12 weeks).

[0016] In some embodiments according to any one of the above methods, the subject is a human.

[0017] It should be understood that one, some, or all of the features of the various embodiments described above and herein may be combined to form other embodiments of the present application. These and other aspects of the present application will be apparent to those skilled in the art. These and other embodiments of the present application are further described in the detailed description that follows. [Brief explanation of the drawings]

[0018] [Figure 1] Cycle 1 and steady-state PK of TY21580 at 3 mg / kg (administered Q3W or Q6W) and steady-state PK of ipilimumab at 1 mg / kg (administered Q6W) are shown. DETAILED DESCRIPTION OF THE INVENTION

[0019] I. Definition Unless otherwise defined herein, scientific and technical terms used in connection with this application shall have the meanings commonly understood by those of ordinary skill in the art. Furthermore, unless the context otherwise requires, singular terms shall include plural referents and plural terms shall include the singular referent. Generally, the nomenclature used in connection with and the techniques of antibody engineering, immunotherapy, cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry described herein are those well known and commonly used in the art.

[0020] The term "antibody" is used herein in the broadest sense and specifically encompasses monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies), and antibody fragments (e.g., Fab, Fab', Fab'-SH, F(ab')2, Fv and / or single-chain variable fragments or scFv), so long as they exhibit the desired biological activity.

[0021] In some embodiments, the term "antibody" refers to an antigen-binding protein (i.e., an immunoglobulin) with a basic four-polypeptide chain structure consisting of two identical heavy (H) chains and two identical light (L) chains. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. Each heavy chain contains a variable region (referred to herein as V) at its N-terminus. H The heavy chain constant region is divided into three domains, C H1 , C H2 , and C H3 Each light chain consists of a variable region (referred to herein as V I The light chain constant region consists of one domain, C L V L is V H Align with C L is aligned with the first constant domain (CH1) of the heavy chain. Hand V L The pairings of these together form a single antigen-binding site. IgM antibodies consist of five basic heterotetrameric units plus an additional polypeptide called the J chain and therefore contain 10 antigen-binding sites, whereas secreted IgA antibodies can polymerize to form multivalent assemblies containing two to five basic four-chain units plus the J chain.

[0022] V H and V L Based on structural and sequence analysis, these regions can be further subdivided into regions of hypervariability called hypervariable regions (HVRs). HVRs are interspersed with more conserved regions called framework regions (FWs) (see, e.g., Chen et al. (1999) J. Mol. Biol. (1999) 293, 865-881). Each VH and VL is composed of three HVRs and four FWs, arranged from amino to carboxy terminus in the following order: FW-1_HVR-1_FW-2_HVR-2_FW-3_HVR-3_FW4. Throughout this application, the three HVRs of the heavy chain are referred to as HVR-H1, HVR-H2, and HVR-H3. Similarly, the three HVRs of the light chain are referred to as HVR-L1, HVR-L2, and HVR-L3.

[0023] As used herein, the term "CDR" or "complementarity determining region" is intended to mean the non-contiguous antigen-binding sites found within the variable regions of both heavy and light chain polypeptides. These specific regions were identified by Kabat et al., J.Biol.Chem.252:6609-6616(1977);Kabat et al.,USDept.of Health and Human Services,“Sequences of proteins of immunological interest”(1991);Chothia et al.,J.Mol.Biol.196:901-917(1987);Al-Lazikani B.et al., J.Mol.Biol.,273:927-948(1997);MacCallum et al., J.Mol.Biol.262:732-745(1996);Abhinandan and Martin, 45:3832-3839(2008);Lefranc MPet al.,Dev. Comp. Immunol.,27:55-77(2003); and Honegger and Pluckthun, J. Mol. Biol., 309:657-670 (2001), and the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to the CDR of an antibody or grafted antibody or variant thereof is intended to be within the scope of the term as defined and used herein. The contents of the references cited in this paragraph, in which CDR prediction algorithms and interfaces are known in the art, including, for example, Mol. Immunol., 45:3832-3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38:D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43:D432-D438 (2015), are hereby incorporated by reference in their entirety for use in this application and for possible inclusion in one or more claims herein.

[0024] Each heavy and light chain variable region contains a binding domain that interacts with an antigen. The antibody constant region can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. Within the light and heavy chains, the variable and constant regions are joined by a "J" region of about 12 or more amino acids, with the heavy chain also containing a "D" region of about 10 or more amino acids (see, e.g., Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, NY) (1989)).

[0025] Light chains from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequence of their constant domains. Antibodies can be assigned to different classes or isotypes depending on the amino acid sequence of the constant domain of their heavy chains (CH). There are five classes of antibodies: IgA, IgD, IgE, IgG, and IgM, each with heavy chains designated α (alpha), δ (delta), ε (epsilon), γ (gamma), and μ (mu). The IgG class of antibodies can be further classified into four subclasses, IgG1, IgG2, IgG3, and IgG4, respectively, based on the gamma heavy chains Y1-Y4.

[0026] The term "CTLA4" is used in this application to include human CTLA4 (e.g., UniProt Accession No. P16410), as well as variants, isoforms, and species homologs thereof (e.g., mouse CTLA4 (UniProt Accession No. P09793), rat CTLA4 (UniProt Accession No. Q9Z1A7), canine CTLA4 (UniProt Accession No. Q9XSI1), cynomolgus monkey CTLA4 (UniProt Accession No. G7PL88), etc.). Thus, anti-CTLA4 antibodies as defined and disclosed herein may also bind to CTLA4 from species other than human. In other cases, anti-CTLA4 antibodies may be completely specific for human CTLA4 and may not exhibit species or other types of cross-reactivity.

[0027] As defined herein, the term "CTLA4 antibody" refers to an antibody capable of binding to human CTLA4.

[0028] The term "epitope" refers to the portion of an antigen to which an antibody (or antigen-binding fragment thereof) binds. Epitopes can be formed from both contiguous amino acids or non-contiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained upon exposure to denaturing solvents, while epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents. Epitopes can comprise a variable number of amino acids in unique spatial conformations. Methods for determining the spatial conformation of epitopes include, for example, X-ray crystallography, two-dimensional nuclear magnetic resonance, deuterium and hydrogen exchange coupled with mass spectrometry, or site-directed mutagenesis, all methods used in conjunction with computational models of the structure of the antigen and its complex with its binding antibody and its variants (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, GE Morris, Ed. (1996)). Once a desired epitope of an antigen has been determined, antibodies against that epitope can be generated, for example, using the techniques described herein. Antibody generation and characterization can also elucidate information about the desired epitope. From this information, it is possible to competitively screen antibodies for binding to the same epitope. One approach to accomplish this is to perform cross-competition studies to discover antibodies that competitively bind to each other, i.e., the antibodies compete for binding to the antigen. A high-throughput process for "binning" antibodies based on mutual competition is described in PCT Publication WO 03 / 48731.

[0029] An "isolated" antibody is one that has been separated from a component of its natural environment. In some embodiments, the antibody is purified to greater than 95% or 99% purity, as determined, for example, by electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reverse-phase HPLC). For a review of methods for assessing antibody purity, see, for example, Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0030] As used herein, "sequence identity" between two polypeptide sequences refers to the percentage of identical amino acids between the sequences.The amino acid sequence identity of polypeptides can be conventionally determined using known computer programs such as Bestfit, FASTA, or BLAST (see, for example, Pearson, Methods Enzymol.183:63-98(1990); Pearson, Methods Mol.Biol.132:185-219(2000); Altschul et al., J. Mol.Biol.215:403-410(1990); Altschul 25:3389-3402(1997)). When using Bestfit or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference amino acid sequence, parameters are set so that the percent identity is calculated over the entire length of the reference amino acid sequence and allows for a difference in homology of up to 5% of the total number of amino acid residues in the reference sequence. This aforementioned method of determining percent identity between polypeptides is applicable to all proteins, fragments, or variants thereof disclosed herein.

[0031] As used herein, the terms "bind," "binds to," "specifically binds to," or "specific for" refer to a measurable and reproducible interaction, such as binding between a target and an antibody, that determines the presence of the target in the presence of a heterogeneous population of molecules, including biological molecules. For example, an antibody that binds to or specifically binds to a target (which may be an epitope) is an antibody that binds to this target with higher affinity, avidity, more readily, and / or for a longer period of time than it binds to other targets. In one embodiment, the extent of binding of an antibody to an unrelated target is less than about 10% of the binding of the antibody to the target, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, an antibody that specifically binds to a target has a dissociation constant (Kd) of 1 μM or less, 100 nM or less, 10 nM or less, 1 nM or less, or 0.1 nM or less. In certain embodiments, an antibody specifically binds to an epitope on a protein that is conserved among proteins from different species. In another embodiment, specific binding can include, but does not require, exclusive binding.

[0032] The terms "treat," "treating," or "treatment," with respect to a particular disease state in a mammal, refer to causing a desirable or beneficial effect in a mammal having the disease state. A desirable or beneficial effect can include reducing the frequency or severity of one or more symptoms of the disease (i.e., tumor growth and / or metastasis, or other effects mediated by immune cell numbers and / or activity, etc.), or preventing or inhibiting further progression of the disease, condition, or disorder. In the context of treating cancer in a mammal, a desirable or beneficial effect can include inhibiting further growth or metastasis of cancer cells, killing cancer cells, inhibiting cancer recurrence, reducing cancer-associated pain, or improving the mammal's survival. The effect can be either subjective or objective. For example, if the animal is a human, the human may note increased vitality or survival, or reduced pain, as subjective symptoms of improvement or therapeutic response. Alternatively, a clinician may note a decrease in tumor size or burden based on physical examination, clinical laboratory values, tumor markers, or radiological findings. Some clinical signs that a clinician may observe regarding a therapeutic response include normalization of laboratory values ​​such as white blood cell count, red blood cell count, platelet count, erythrocyte sedimentation rate, and various enzyme levels. Additionally, a clinician may observe a decrease in detectable tumor markers. Alternatively, other tests, such as ultrasound imaging, nuclear magnetic resonance imaging, and positron emission tomography, may be used to assess objective improvement.

[0033] The terms "preventing" or "prevention" with respect to a particular disease state in a mammal refer to preventing or delaying the onset of the disease or preventing the manifestation of its clinical or subclinical symptoms.

[0034] As used herein, a "subject," "patient," or "individual" may refer to a human or a non-human animal. A "non-human animal" may refer to any animal not classified as a human, such as farm, livestock, or zoo animals, sport animals, pet animals (e.g., dogs, horses, cats, cows, etc.), and animals used in research. Research animals may refer to, but are not limited to, nematodes, arthropods, vertebrates, mammals, frogs, rodents (e.g., mice or rats), fish (e.g., zebrafish or pufferfish), birds (e.g., chickens), dogs, cats, and non-human primates (e.g., rhesus monkeys, cynomolgus monkeys, chimpanzees, etc.). In some embodiments, the subject, patient, or individual is a human.

[0035] An "effective amount" refers to at least an amount effective, at dosages and for periods of time necessary, to achieve one or more desired or indicated effects, including therapeutic or prophylactic results. An effective amount can be given in one or more administrations. For purposes of this application, an effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to directly or indirectly achieve prophylactic or therapeutic treatment. As understood in a clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition (e.g., an effective amount when administered as monotherapy or combination therapy). Thus, an "effective amount" may be considered in the context of administration of one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desired result can be or is achieved.

[0036] The terms "recurrence," "recurrence," or "recurrence" refer to the recurrence of cancer or disease after clinical assessment of disease resolution. A diagnosis of distant metastasis or local recurrence may be considered a recurrence.

[0037] The terms "refractory" or "resistant" refer to a cancer or disease that has not responded to treatment.

[0038] As used herein, "complete response" or "CR" refers to the disappearance of all target lesions, "partial response" or "PR" refers to at least a 30% reduction in the sum of the longest diameters (SLD) of the target lesions, based on baseline SLD, and "stable disease" or "SD" refers to neither sufficient shrinkage of target lesions since initiating treatment to qualify for PR nor sufficient increase to qualify for PD, based on the smallest SLD,

[0039] As used herein, "disease progression" or "PD" refers to at least a 20% increase in the SLD of a target lesion or the presence of one or more new lesions, based on the smallest SLD recorded since the start of treatment.

[0040] As used herein, "progression-free survival" (PFS) refers to the length of time during and after treatment during which the disease being treated (e.g., cancer) does not worsen. Progression-free survival can include the amount of time a patient experiences a complete response or a partial response, as well as the amount of time a patient experiences stable disease.

[0041] As used herein, "overall response rate" (ORR) refers to the sum of the complete response (CR) rate and the partial response (PR) rate.

[0042] As used herein, "overall survival rate" refers to the proportion of individuals in a group who are likely to be alive after a specified period of time.

[0043] As used herein, "baseline level" or "baseline value" refers to a subject's level or value before the subject begins treatment, such as anti-CTLA4 antibody treatment.

[0044] As used herein, a "reference sample," "reference cell," "reference tissue," "control sample," "control cell," or "control tissue" refers to a sample, cell, tissue, standard, or level used for comparison purposes. In one embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and / or non-diseased part of the body (e.g., tissue or cells) of the same subject or individual. For example, a healthy and / or non-diseased cell or tissue adjacent to a diseased cell or tissue (e.g., a cell or tissue adjacent to a tumor). In another embodiment, the reference sample is obtained from an untreated tissue and / or cells of the body of the same subject or individual. In yet another embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy and / or non-diseased part of the body (e.g., tissue or cells) of an individual other than the subject or individual. In yet another embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from untreated tissues and / or cells from the body of an individual other than the subject or individual.

[0045] An "effective response" and similar expressions of a patient or a patient's "responsiveness" to treatment with an agent refer to a clinical or therapeutic benefit conferred on a patient at risk for or suffering from a disease or disorder, such as cancer. In one embodiment, such benefit includes any one or more of extending survival (including overall survival and progression-free survival), producing an objective response (including a complete or partial response), or ameliorating the signs or symptoms of cancer.

[0046] A patient who "does not respond effectively" to treatment is one who does not have any of the following: an extension of survival (including overall survival and progression-free survival), an objective response (including a complete response or a partial response), or an improvement in the signs or symptoms of cancer.

[0047] The methods and techniques of the present application are generally carried out according to methods well known in the art and as described in various general and more specific references cited and discussed throughout the specification, unless otherwise indicated. Such references include, for example, Sambrook and Russell, Molecular Cloning, A Laboratory Approach, Cold Spring Harbor Press, Cold Spring Harbor, NY (2001); Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY (2002); and Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1990). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications, as commonly practiced in the art, or as described herein. The nomenclatures used in connection with, and the laboratory procedures and methods of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are well known and commonly used in the art. Standard methods are used for chemical synthesis, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

[0048] As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Immunology—A Synthesis (2nd Edition, E.S. Golub and D.R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)).

[0049] As used herein, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a "molecule" includes any combination of two or more such molecules, and so forth.

[0050] As used herein, the term "about" refers to a customary error range for each value, which is readily understood by one of ordinary skill in the art. Reference herein to "about" a value or parameter includes (and describes) embodiments that refer to that value or parameter in itself.

[0051] It is to be understood that the aspects and embodiments of the present application described herein include "comprising," "consisting of," and "consisting essentially of" aspects and embodiments.

[0052] As used herein, reference to a value or parameter "not" generally means and describes "other than" the value or parameter. For example, a method is not used to treat cancer type X means that the method is used to treat cancers other than type X.

[0053] As used herein, the term "about X to Y" has the same meaning as "about X to about Y."

[0054] The term "and / or," when used herein in expressions such as "A and / or B," is intended to include both "A and B," "A or B," "A" (alone), and "B" (alone). Similarly, as used herein, phrases such as the term "and / or," "A, B and / or C," are intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0055] II. Treatment method The present application provides methods of treating cancer in a subject using anti-CTLA4 antibodies that specifically bind to human CTLA4. Any one of the anti-CTLA4 antibodies in Section III, "Anti-CTLA4 Antibodies," including full-length antibodies and antigen-binding fragments thereof, can be used in the methods described herein.

[0056] In some embodiments, methods are provided for treating cancer in a subject, comprising administering to the subject an effective amount of an anti-CTLA4 antibody that specifically binds to an epitope including amino acid residues Y105 and L106 but not including residue I108 of human CTLA4, where amino acid residue numbering is based on SEQ ID NO: 108, wherein the cancer is resistant or refractory to conventional treatment, and the conventional treatment is an inhibitor of CTLA4, PD-1, or PD-1 ligand.

[0057] In some embodiments, a method of treating cancer in a subject is provided, comprising administering to the subject an effective amount of an anti-CTLA4 antibody that specifically binds to an epitope including amino acid residues Y105 and L106 but not residue I108 of human CTLA4, where amino acid residue numbering is based on SEQ ID NO: 108, and wherein the cancer is resistant or refractory to a different anti-CTLA4 antibody, such as ipilimumab.

[0058] In some embodiments, methods are provided for treating cancer in a subject, the methods comprising administering to the subject an effective amount of an anti-CTLA4 antibody that specifically binds to an epitope including amino acid residues Y105 and L106, but not including residue I108, of human CTLA4, where amino acid residue numbering is based on SEQ ID NO: 108, and the cancer is resistant or refractory to inhibitors of PD-1 or a PD-1 ligand (PD-L1 or PD-L2).

[0059] In some embodiments, methods are provided for treating cancer in a subject, comprising administering to the subject an effective amount of an anti-CTLA4 antibody that specifically binds to an epitope including amino acid residues Y105 and L106, but not including residue I108, of human CTLA4, where amino acid residue numbering is based on SEQ ID NO: 108, wherein the cancer is resistant or refractory to an anti-PD-1 antibody.

[0060] In some embodiments, methods are provided for treating a subject's cancer that is resistant or refractory to an inhibitor of CTLA4, PD-1, or PD-1 ligand (PD-L1 or PD-L2), comprising administering to the subject an effective amount of an anti-CTLA4 antibody, wherein the antibody comprises: (a) a heavy chain variable region comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45, and / or a light chain variable region comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the cancer is resistant or refractory to an anti-PD-1 antibody. In some embodiments, the cancer is resistant or refractory to a different anti-CTLA4 antibody, such as ipilimumab. In some embodiments, the cancer is resistant or refractory to an anti-PD-L1 antibody. In some embodiments, the cancer is a solid cancer, such as an advanced stage cancer and / or a metastatic cancer. In some embodiments, the cancer is a urothelial carcinoma. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 87, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises the Fc region of a human IgG1, such as a wild-type IgG1 Fc region or a variant with enhanced ADCC activity. In some embodiments, the antibody is TY21580.

[0061] In some embodiments, a method of treating cancer in a subject is provided, comprising administering to the subject an effective amount of an anti-CTLA4 antibody that specifically binds to an epitope comprising amino acid residues Y105 and L106 but not residue I108 of human CTLA4, where amino acid residue numbering is based on SEQ ID NO: 108, wherein the anti-CTLA4 antibody is administered at a dose of at least about 6 mg / kg (e.g., 6 mg / kg or 10 mg / kg). In some embodiments, the anti-CTLA4 antibody comprises: (a) a heavy chain variable region comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35, and HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45, and / or a light chain variable region comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 87, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises the Fc region of a wild-type IgG1 or a human IgG1 Fc region, such as a variant with enhanced ADCC activity. In some embodiments, the antibody is TY21580. In some embodiments, the anti-CTLA4 antibody is administered approximately once every three weeks. In some embodiments, the anti-CTLA4 antibody is administered intravenously. In any of the foregoing embodiments, the anti-CTLA4 antibody can be administered as monotherapy.

[0062] In some embodiments, methods are provided for treating cancer in a subject, the methods comprising administering to the subject (a) an effective amount of an anti-CTLA4 antibody that specifically binds to an epitope including amino acid residues Y105 and L106, but not including residue I108, of human CTLA4, where amino acid residue numbering is based on SEQ ID NO: 108, and (b) an effective amount of an anti-PD-1 antibody. Exemplary anti-PD-1 antibodies include 2E5 (Cstone Pharmaceuticals), tislelizumab (BGB-A317), BGB-108, STI-A1110, AM0001, BI754091, sintilimab (IBI308), cetrelimab (JNJ-63723283), toripalimab (JS-001), camrelizumab (SHR-1210, INCSHR-1210, HR-301210), MEDI-0680 (AMP-514), MGA-012 (INCMGA 0012), nivolumab (BMS-936558, MDX1106, ONO-4538), spartalizumab (PDR00l), PF-06801591, cemiplimab (REGN-2810, REGEN2810), dostallimab (TSR-042, ANB011), pidilizumab (CT-011), FITC-YT-16 (PD-1 binding peptide), APL-501, CBT-501 or geptanolimab (GB-226), AB-122, AK105, AMG404, BCD-100, F520, HLX10, HX008, JTX-4014, LZM009, Sym021, PSB205, AMP-224 (fusion protein targeting PD-1), CX-188 (PD-1 probody), AGEN-2034, GLS-010, budigalimab (ABBV-181), AK-103, BAT-1306, CS-1003, AM-0001, TILT-123, BH-2922, BH-2941, BH-2950, ​​ENUM-244C8, ENUM-388D4, HAB-21, H EISCOI 11-003, IKT-202, MCLA-134, MT-17000, PEGMP-7, PRS-332, RXI-762, STI-1110, VXM-10, XmAb-2 3104, AK-112, HLX-20, SSI-361, AT-16201, SNA-01, AB122, PD1-PIK, PF-06936308, RG-7769, CABAnti-PD-1 antibodies include, but are not limited to, PD-1 Abs, AK-123, MEDI-3387, MEDI-5771, 4H1128Z-E27, REMD-288, SG-001, BY-24.3, CB-201, IBI-319, ONCR-177, Max-1, CS-4100, JBI-426, CCC-0701, CCX-4503, biosimilars thereof, and derivatives thereof. In some embodiments, art-recognized antibodies that compete with any of these antibodies for binding to PD-1 can also be used. In some embodiments, the anti-PD-1 antibody is 2E5. 2E5 and related anti-PD-1 antibodies are described, for example, in CN107840887A, which is incorporated herein by reference in its entirety. In some embodiments, the anti-PD-1 antibody is toripalimab. Toripalimab and related anti-PD-1 antibodies are described, for example, in US10066013B2, which is incorporated herein by reference in its entirety.

[0063] In some embodiments, the anti-PD-1 antibody is toripalimab, a biosimilar thereof, or a derivative thereof. In some embodiments, the anti-PD-1 antibody comprises a VH and a VL, wherein the VH comprises a CDR-H1 comprising the amino acid sequence of DYEMH (SEQ ID NO: 109), a CDR-H2 comprising the amino acid sequence of VIESETGGTAYNQKFKG (SEQ ID NO: 110), and a CDR-H3 comprising the amino acid sequence of EGITTVATTYYWYFDV (SEQ ID NO: 111), and the VL comprises a CDR-L1 comprising the amino acid sequence of RSSQSIVHSNGNTYLE (SEQ ID NO: 112), a CDR-L2 comprising the amino acid sequence of KVSNRFS (SEQ ID NO: 113), and a CDR-L3 comprising the amino acid sequence of FQGSHVPLT (SEQ ID NO: 114). In some embodiments, the anti-PD-1 antibody comprises a VH comprising the amino acid sequence of QGQLVQSGAEVKKPGASVKVSCKASGYTFTDYEMHWVRQAPIHGLEWIGVIESETGGTAYNQKFKGRVTITADKSTSTAYMELSSLRSEDTAVYYCAREGITTVATTYYWYFDVWGQGTTVTVSS (SEQ ID NO: 115) and / or a VL comprising the amino acid sequence of DVVMTQSPLSLPVTLGQPASISCRSSQSIVHSNGNTYLEWYLQKPGQSPQLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPLTFGQGTKLEIK (SEQ ID NO: 116). In some embodiments, an effective amount of the anti-PD-1 antibody is administered at about 1 mg / kg to about 10 mg / kg. In some embodiments, the dose of the anti-PD1 antibody is 1 mg / kg. In some embodiments, the dose of the anti-PD1 antibody is 5 mg / kg. In some embodiments, the dose of the anti-PD1 antibody is 10 mg / kg. In some embodiments, the anti-PD-1 antibody is administered at a dose of about 240 mg. In some embodiments, the anti-PD-1 antibody is administered intravenously. In some embodiments, the anti-PD-1 antibody is administered every three weeks. In some embodiments, the cancer is selected from the group consisting of renal cell carcinoma, non-small cell lung cancer, hepatocellular carcinoma, and microsatellite instability-high or mismatch repair deficient cancer.

[0064] In some embodiments in which an anti-CTLA4 antibody is administered in combination with an anti-PD-1 antibody, the anti-CTLA4 antibody comprises (a) a heavy chain variable region comprising HVR-H1 comprising the amino acid sequence of SEQ ID NO:23, HVR-H2 comprising the amino acid sequence of SEQ ID NO:35, and HVR-H3 comprising the amino acid sequence of SEQ ID NO:45, and / or a light chain variable region comprising HVR-L1 comprising the amino acid sequence of SEQ ID NO:58, HVR-L2 comprising the amino acid sequence of SEQ ID NO:66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO:75. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:87 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:87, and / or a light chain variable region comprising the amino acid sequence of SEQ ID NO:100 or an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:100. In some embodiments, the antibody comprises a human IgG1 Fc region, such as a wild-type IgG1 Fc region or a variant with enhanced ADCC activity. In some embodiments, the antibody is TY21580. In some embodiments, the anti-CTLA4 antibody is administered at a dose of at least about 1 mg / kg (e.g., 2 mg / kg, 3 mg / kg, or 6 mg / kg). In some embodiments, the anti-CTLA4 antibody is administered about once every three weeks. In other embodiments, the anti-CTLA4 antibody is administered about once every six weeks. In some embodiments, the anti-CTLA4 antibody is administered intravenously. In some embodiments, the cancer is resistant or refractory to inhibitors of CTLA-4, PD-1, or PD-1 ligands (e.g., PD-L1 or PD-L2). In some embodiments, the cancer is a solid cancer, such as an advanced and / or metastatic cancer. In some embodiments, the cancer is urothelial carcinoma. Cancer treatment can be evaluated by, for example, tumor regression, reduction in tumor weight or size, time to progression, survival, progression-free survival, overall response rate, duration of response, quality of life, protein expression, and / or activity. Approaches to determine the efficacy of therapy can be used, including, for example, measuring response by radiological imaging.

[0065] The anti-CTLA4 antibodies and compositions provided by the present disclosure can be administered via any suitable enteral or parenteral route of administration. The term "enteral route" of administration refers to administration via any part of the gastrointestinal tract. Examples of enteral routes include oral, mucosal, buccal, and rectal routes, or intragastric routes. A "parenteral route" of administration refers to a route of administration other than the enteral route. Examples of parenteral routes of administration include intravenous, intramuscular, intradermal, intraperitoneal, intratumoral, intravesical, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, and intrasternal, subcutaneous, or topical administration. The antibodies and compositions of the present disclosure can be administered using any suitable method, such as oral ingestion, nasogastric tube, gastrostomy tube, injection, infusion, implantable infusion pump, and osmotic pump. Suitable routes and methods of administration can vary depending on many factors, such as the particular antibody used, the desired rate of absorption, the particular formulation or dosage form used, the type or severity of the disorder being treated, the particular site of action, and the condition of the patient, and can be readily selected by one of skill in the art. In some embodiments, the anti-CTLA4 antibody is administered intravenously.

[0066] An effective amount of an anti-CTLA4 antibody can be administered in a single dose or multiple doses. For methods involving administration of multiple doses of an anti-CTLA4 antibody, exemplary administration frequencies include, but are not limited to, weekly, weekly without interruption, two weeks out of three weeks, three weeks out of four weeks, once every three weeks, once every two weeks, monthly, every six months, and annually. In some embodiments, the anti-CTLA4 antibody is administered approximately once a week, once every two weeks, once every three weeks, once every six weeks, or once every 12 weeks. In some embodiments, the interval between each administration is approximately 3 years, 2 years, 12 months, 11 months, 10 months, 9 months, 8 months, 7 months, 6 months, 5 months, 4 months, 3 months, 2 months, 1 month, 4 weeks, 3 weeks, 2 weeks, or less than one week. In some embodiments, the interval between each administration is about 1 week, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 2 years, or more than 3 years. In some embodiments, there is no break in the administration schedule.

[0067] In some embodiments, the anti-CTLA4 antibody is administered infrequently, for example, once a week, once every two weeks, once every three weeks, once a month, once every two months, once every three months, once every four months, once every five months, once every six months, once every seven months, once every eight months, once every nine months, once every ten months, once every eleven months, or once a year, or less frequently. In some embodiments, the anti-CTLA4 antibody is administered in a single dose. In some embodiments, the anti-CTLA4 antibody is administered approximately once every three weeks.

[0068] In some embodiments, the anti-CTLA4 antibody is administered for two or more cycles, for example, any one of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles, hi some embodiments, the anti-CTLA4 antibody is administered for at least four cycles.

[0069] Anti-CTLA4 antibodies can be administered to patients as monotherapy or in combination with other therapeutic agents (e.g., anti-PD-1 antibodies) at doses that enhance receptor (CTLA-4) occupancy, making them effective with minimal side effects. Thus, the anti-CTLA4 antibodies of the present invention have an improved therapeutic index compared to anti-CTLA4 antibodies such as ipilimumab. For example, in one embodiment, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. The anti-CTLA4 antibody can be administered as a single dose (monotherapy or in combination with one or more therapeutic agents) that achieves greater than 50% receptor occupancy three or six weeks after administration. In some embodiments, the anti-CTLA4 antibody can be administered as a single dose that achieves greater than 60% receptor occupancy three weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose that achieves greater than 70% receptor occupancy three weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose to achieve greater than 80% receptor occupancy three weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose to achieve about 50% to about 80% receptor occupancy three weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose to achieve about 60% to about 75% receptor occupancy three weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose to achieve greater than 60% receptor occupancy six weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose to achieve greater than 70% receptor occupancy six weeks after administration. In other such embodiments, the anti-CTLA4 antibody can be administered as a single dose to achieve about 50% to about 70% receptor occupancy six weeks after administration. In any of the foregoing embodiments, the anti-CTLA4 antibody can be administered in combination with an anti-PD-1 antibody, as disclosed herein.

[0070] In one embodiment, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. The antibody can be administered to a subject at a dose of about 1 mg / kg to about 10 mg / kg or about 2 mg / kg to about 5 mg / kg. In some embodiments, the anti-CTLA4 antibody can be administered to a subject at a dose of about 3 mg / kg. In some embodiments, the anti-CTLA4 antibody can be administered to a subject once every three weeks. In other embodiments, the anti-CTLA4 antibody can be administered to a subject once every six weeks. In a specific embodiment, the antibody TY21580 can be administered to a patient at a dose of about 3 mg / kg once every three weeks or once every six weeks.

[0071] In some embodiments, the treatment comprises an initial phase followed by a maintenance phase. In some embodiments, the anti-CTLA4 antibody is administered less frequently in the maintenance phase than in the initial phase. In some embodiments, the anti-CTLA4 antibody is administered at the same frequency in the maintenance phase as in the initial phase. In some embodiments, the treatment comprises an initial phase in which the anti-CTLA4 antibody is administered about once every 3 weeks for at least 4 cycles, and a maintenance phase in which the anti-CTLA4 antibody is administered about once every 4 weeks to once every 12 weeks, for example, once every 4 weeks, once every 6 weeks, once every 8 weeks, once every 10 weeks, or once every 12 weeks. In some embodiments, the administration frequency in the maintenance phase is T reg cells, CD8+T em cells, CD4+T em cells, CD8+T em Cells and T reg Ratio to CD4+T cells em Cells and T reg For example, if a subject is administered an anti-CTLA4 antibody and the subject is subsequently treated with an anti-CTLA4 antibody, the subject may be adjusted according to one or more biomarkers, such as the ratio of CD8+ T cells to NK cells, and / or the ratio of NK cells to NK cells. em Cells and T reg If the subject shows an increased ratio of CTLA4 cells, the subject can be further administered an anti-CTLA4 antibody about once every four weeks.

[0072] Administration of the anti-CTLA4 antibody can be extended over an extended period of time, for example, from about 1 week to about 1 month, from about 1 month to about 1 year, from about 1 year to about several years, etc. In some embodiments, the anti-CTLA4 antibody is administered for at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 1 year, 2 years, 3 years, 4 years, or more.

[0073] The methods described herein are useful for treating a variety of cancers. In some embodiments, the cancer is a solid cancer. In some embodiments, the cancer is a liquid cancer. Various cancers in which CTLA4 is involved, whether malignant or benign, and whether primary or secondary, can be treated or prevented using the methods provided by the present disclosure. Examples of cancers include, but are not limited to, liver cancer, cancers of the digestive system (e.g., colon cancer, colorectal cancer), lung cancer, bone cancer, heart cancer, brain cancer, kidney cancer, bladder cancer, blood cancer (e.g., leukemia), skin cancer, breast cancer, thyroid cancer, pancreatic cancer, head and neck cancer, eye-related cancer, cancers of the male reproductive system (e.g., prostate cancer, testicular cancer), or cancers of the female reproductive system (e.g., uterine cancer, cervical cancer). In some embodiments, the cancer is kidney cancer, such as renal cell carcinoma, or urothelial carcinoma. In some embodiments, the cancer is a cold tumor. In some embodiments, the cancer is resistant or refractory to one or more conventional treatments, such as immunotherapy, including immune checkpoint inhibitors. In some embodiments, the cancer is a tumor that cannot be penetrated by T cells because the tumor is not recognized by the immune system or does not elicit an immune response.

[0074] In certain embodiments, the anti-CTLA4 antibodies of the present disclosure can be used to treat Kaposi's sarcoma. In some embodiments, the anti-CTLA4 antibody is administered as monotherapy. In other such embodiments, an anti-CTLA4 antibody and an additional therapeutic reagent, particularly an anti-PD-1 antibody, are used. In any of the foregoing embodiments, the anti-CTLA4 antibody can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. In some embodiments, the anti-CTLA4 antibody is TY21580.

[0075] In certain embodiments, the anti-CTLA4 antibodies of the present disclosure can be used to treat head and neck squamous cell carcinoma (HNSCC). In some embodiments, the anti-CTLA4 antibody is administered as monotherapy. In other such embodiments, an anti-CTLA4 antibody and an additional therapeutic reagent, particularly an anti-PD-1 antibody, are used. In any of the foregoing embodiments, the anti-CTLA4 antibody can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. In some embodiments, the anti-CTLA4 antibody is TY21580.

[0076] In certain embodiments, the anti-CTLA4 antibodies of the present disclosure can be used to treat pancreatic cancer. In some embodiments, the anti-CTLA4 antibody is administered as monotherapy. In other such embodiments, an anti-CTLA4 antibody and an additional therapeutic reagent, particularly an anti-PD-1 antibody, are used. In any of the foregoing embodiments, the anti-CTLA4 antibody can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. In some embodiments, the anti-CTLA4 antibody is TY21580.

[0077] In certain embodiments, the anti-CTLA4 antibodies of the present disclosure can be used to treat ovarian cancer. In some embodiments, the anti-CTLA4 antibody is administered as monotherapy. In other such embodiments, an anti-CTLA4 antibody and an additional therapeutic reagent, particularly an anti-PD-1 antibody, are used. In any of the foregoing embodiments, the anti-CTLA4 antibody can comprise a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. In some embodiments, the anti-CTLA4 antibody is TY21580.

[0078] In some embodiments, the subject has previously been treated for cancer with conventional therapy. In some embodiments, the subject has previously received one, two, three, four, or more conventional therapies. In some embodiments, the subject has previously exhausted all other available therapies. In some embodiments, the subject is unresponsive or resistant to conventional therapy. In some embodiments, the subject has relapsed after conventional therapy. In some embodiments, the cancer is refractory to conventional therapy. In some embodiments, the subject has failed conventional therapy within about one year, six months, or three months. In some embodiments, the subject has not previously received conventional therapy.

[0079] In some embodiments, the subject has previously received standard treatment for cancer. In some embodiments, the subject is unresponsive or resistant to standard treatment. In some embodiments, the subject has disease recurrence after standard treatment. In some embodiments, the cancer is refractory to standard treatment. In some embodiments, the subject has failed standard treatment within about 1 year, 6 months, or 3 months. In some embodiments, the subject has not previously received standard treatment. In some embodiments, the subject has refused standard treatment or is ineligible for standard treatment.

[0080] In some embodiments, the conventional therapy (e.g., standard of care) is selected from the group consisting of viral gene therapy, immunotherapy, targeted therapy, radiation therapy, and chemotherapy. In some embodiments, the conventional therapy is an immune checkpoint inhibitor. In some embodiments, the conventional therapy is an inhibitor of CTLA4, PD-1, or a PD-1 ligand (e.g., PD-L1 or PD-L2). In some embodiments, the conventional therapy is an inhibitor of CTLA4, e.g., an anti-CTLA4 antibody different from the anti-CTLA4 antibodies described herein. In some embodiments, the conventional therapy is ipilimumab.

[0081] In some embodiments, the conventional therapy is an inhibitor of PD-1 or PD-1 ligand, including a PD-1 binding antagonist, a PDL1 binding antagonist, and a PDL2 binding antagonist. Other names for "PD-1" include CD279 and SLEB2. Other names for "PDL1" include B7-H1, B7-4, CD274, and B7-H. Other names for "PDL2" include B7-DC, Btdc, and CD273. In some embodiments, the PD-1, PDL1, and PDL2 are human PD-1, PDL1, and PDL2.

[0082] In some embodiments, the inhibitor of PD-1 is a molecule that inhibits the binding of PD-1 to its ligand binding partner. In some embodiments, the inhibitor of PD-1 ligand is an inhibitor of PD-L1 and / or PD-L2. In some embodiments, the inhibitor of PD-L1 is a molecule that inhibits the binding of PDL1 to its binding partner. In some embodiments, the PD-L2 binding partner is PD-1 and / or B7-1. In some embodiments, the PD-1 ligand is a molecule that inhibits the binding of PD-L2 to its binding partner. In some embodiments, the PD-L2 binding partner is PD-1. The inhibitor can be an antibody, antigen-binding fragment thereof, immunoadhesin, fusion protein, or oligopeptide.

[0083] In some embodiments, the inhibitor of PD-1 is an anti-PD-1 antibody (eg, a human antibody, a humanized antibody, or a chimeric antibody).In some embodiments, the anti-PD-1 antibody is selected from the group consisting of 2E5 (Cstone Pharmaceuticals), tislelizumab (BGB-A317), BGB-108, STI-A1110, AM0001, BI754091, sintilimab (IBI308), cetrelimab (JNJ-63723283), toripalimab (JS-001), camrelizumab (SHR-1210, INCSHR-1210, HR-301210), MEDI-0680 (AMP-514), MGA-012 (INCMGA 0012), nivolumab (BMS-936558, MDX1106, ONO-4538), spartalizumab (PDR00l), PF-06801591, cemiplimab (REGN-2810, REGEN2810), dostallimab (TSR-042, ANB011), pidilizumab (CT-011), FITC-YT-16 (PD-1 binding peptide), APL-501, CBT-501 or geptanolimab (GB-226), AB-122, AK105, AMG404, BCD-100, F520, HLX10, HX008, JTX-4014, LZM009, Sym021, PSB205, AMP-224 (fusion protein targeting PD-1), CX-188 (PD-1 probody), AGEN-2034, GLS-010, budigalimab (ABBV-181), AK-103, BAT-1306, CS-1003, AM-0001, TILT-123, BH-2922, BH-2941, BH-2950, ​​ENUM-244C8, ENUM-388D4, HAB-21, H EISCOI 11-003, IKT-202, MCLA-134, MT-17000, PEGMP-7, PRS-332, RXI-762, STI-1110, VXM-10, XmAb-2 3104, AK-112, HLX-20, SSI-361, AT-16201, SNA-01, AB122, PD1-PIK, PF-06936308, RG-7769, CAB PD-1 Abs, AK-123, MEDI-3387, MEDI-5771, 4H1128Z-E27, REMD-288, SG-001, BY-24.3, CB-201, IBI-319, ONCR-177, Max-1, CS-4100, JBI-426, CCC-0701, CCX-4503, biosimilars thereof, or derivatives thereof.In some embodiments, the anti-PD-1 antibody is selected from the group consisting of nivolumab and CT-011. In some embodiments, the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1-binding portion of PDL1 or PDL2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence). In some embodiments, the PD-1 inhibitor is AMP-224. In some embodiments, the anti-PD-1 antibody is nivolumab (CAS Registry Number: 946414-94-4). Nivolumab, also known as MDX-1106-04, MDX-1106, ONO-4538, BMS-936558, and OPDIVO®, is an anti-PD-1 antibody described in WO 2006 / 121168. CT-011, also known as hBAT or hBAT-1, is an anti-PD-1 antibody described in WO2009 / 101611. AMP-224, also known as B7-DCIg, is a PDL2-Fc fusion soluble receptor described in WO2010 / 027827 and WO2011 / 066342.

[0084] In some embodiments, the PD-L1 inhibitor is an anti-PD-L1 antibody. In some embodiments, the PD-L1 inhibitor is YW243.55.S70, MPDL3280A, MDX-1105, or MEDI4736. MDX-1105, also known as BMS-936559, is an anti-PD-L1 antibody described in WO2007 / 005874. Antibody YW243.55.S70 (heavy and light chain variable region sequences are set forth in SEQ ID NOs: 20 and 21, respectively) is an anti-PD-L1 antibody described in WO2010 / 077634A1. MEDI4736 is an anti-PD-L1 antibody described in WO2011 / 066389 and US2013 / 034559. Examples of anti-PD-L1 antibodies useful in the methods of the present application, and methods for making them, are described in PCT Patent Application No. WO2010 / 077634 A1 and U.S. Patent No. 8,217,149, which are incorporated herein by reference.

[0085] Conventional treatments (e.g., standard treatments) also include surgery to remove tumors and radiation therapy. Exemplary radiation treatments include, but are not limited to, ionizing (electromagnetic) radiation therapy (e.g., X-rays or gamma rays) and particle radiation therapy (e.g., high linear energy radiation). The source of radiation can be external or internal to the subject.

[0086] The methods described herein are useful in various aspects of cancer treatment. In some embodiments, provided are methods of inhibiting cell proliferation (e.g., tumor growth) in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein. In some embodiments, cell proliferation is inhibited by at least about 10% (including, for example, at least about any of 20%, 30%, 40%, 60%, 70%, 80%, 90%, 95% or more).

[0087] In some embodiments, provided are methods of inhibiting tumor metastasis in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein, in which at least about 10% (including, for example, at least about any of 20%, 30%, 40%, 60%, 70%, 80%, 90%, 95% or more) of metastasis is inhibited.

[0088] In some embodiments, methods are provided for reducing (e.g., eliminating) existing tumor metastasis (e.g., lymph node metastasis) in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein. In some embodiments, metastasis is reduced by at least about 10% (including, for example, at least about any of 20%, 30%, 40%, 60%, 70%, 80%, 90%, 95% or more).

[0089] In some embodiments, methods are provided for reducing the incidence or burden of existing tumor metastases (e.g., lymph node metastases) in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein.

[0090] In some embodiments, methods are provided for reducing tumor size in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein. In some embodiments, the method reduces tumor size by at least about 10% (including, for example, at least about any of 20%, 30%, 40%, 60%, 70%, 80%, 90%, 95% or more).

[0091] In some embodiments, methods are provided for extending the time to disease progression of cancer in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein. In some embodiments, the method extends the time to disease progression by at least 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 28 weeks, 32 weeks, 36 weeks, or more.

[0092] In some embodiments, methods are provided for extending survival (e.g., overall survival or progression-free survival) of an individual with cancer, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein. In some embodiments, the method extends the individual's survival by at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, or 24 months.

[0093] In some embodiments, methods are provided for alleviating one or more symptoms in an individual, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein.

[0094] In some embodiments, methods are provided for improving the quality of life of an individual with cancer, comprising administering to the individual an effective amount of any one of the anti-CTLA4 antibodies described herein.

[0095] The anti-CTLA4 antibody may be administered alone as monotherapy or in combination with one or more additional therapeutic agents or treatments. In some embodiments, the anti-CTLA4 antibody is administered in combination with one or more additional therapeutic agents for separate, sequential, or simultaneous administration. The term "additional therapeutic agent" refers to any therapeutic agent other than the anti-CTLA4 antibody provided by the present disclosure. In some embodiments, a combination therapy for treating cancer in a subject is provided, the combination therapy comprising administering to the subject an effective amount of an anti-CTLA4 antibody described herein in combination with one or more additional therapeutic agents. In some embodiments, the anti-CTLA4 antibody is administered in combination with one or more additional therapeutic agents, including a chemotherapeutic agent, an immunotherapeutic agent, and / or a hormonal therapy agent. In some embodiments, the one or more therapeutic agents are selected from the group consisting of viral gene therapy, immune checkpoint inhibitors, targeted therapy, radiation therapy, vaccine therapy, and chemotherapy. In certain embodiments, at least one of the additional therapeutic agents is an anti-PD-1 antibody, as described herein.

[0096] III. Anti-CTLA4 antibody The methods described herein include administering anti-CTLA4 antibodies that specifically bind to human CTLA4, including CTLA4 antibodies, antigen-binding fragments of CTLA4 antibodies, and derivatives of CTLA4 antibodies. Exemplary anti-CTLA4 antibodies are described, for example, in International Publication No. WO2019149281A1, which is incorporated herein by reference in its entirety.

[0097] In some embodiments, the anti-CTLA4 antibody is any one of the antibodies described herein, including those described in terms of HVRs, variable regions (VL, VH), and specific amino acid sequences of the light and heavy chains (e.g., IgG1, IgG2, IgG4). In some embodiments, the antibody is a human antibody. In some embodiments, the antibody is a humanized antibody and / or a chimeric antibody. In some embodiments, the anti-CTLA4 antibody binds to human CTLA4 and has the following functional properties: (a) binds to human, cynomolgus monkey, mouse, rat, and / or dog CTLA4 with a KD of 500 nM or less; (b) has antagonist activity against human CTLA4; (c) does not bind to human PD-1, PD-L1, PD-L2, LAG3, TIM3, B7-H3, CD95, CD120a, OX40, CD40, BTLA, VISTA, ICOS, and / or B7-H4 at concentrations up to 100 nM; and (d) interacts with monkey, mouse, rat, and / or dog CTLA4. (e) differential reactivity, (e) induce ADCC effects (e.g., against Tregs), (f) activate human PBMCs (e.g., stimulate IL-2 and / or IFNγ secretion), (g) can inhibit tumor cell proliferation, (h) have a therapeutic effect against cancer, and (i) block the binding of human CTLA4 to human CD80 and / or human CD86 (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, or all nine of these). In some embodiments, the anti-CTLA4 antibodies described herein have reduced activity in blocking the binding of CD80 and / or CD86 to human CTLA4 compared to ipilimumab in assays in which human CD80 and / or CD86 are immobilized (or bound to a plate) or human CTLA4 protein is present on the cell surface. In some embodiments, the anti-CTLA4 antibodies described herein selectively deplete Treg cells in the tumor microenvironment compared to Treg depletion in PBMCs or the spleen. In some embodiments, the anti-CTLA4 antibodies described herein have greater Treg depletion activity in the tumor microenvironment compared to ipilimumab.Also provided herein is one or more anti-CTLA4 antibodies or antigen-binding fragments that cross-compete with one or more of the antibodies or antigen-binding fragments described herein for binding to human CTLA4.

[0098] In some embodiments, the antibody or antigen-binding fragment has a K for human, cynomolgus monkey, mouse, rat, and / or dog CTLA4 of about 500 nM or less (e.g., about 500 nM or less, about 450 nM or less, about 400 nM or less, about 350 nM or less, about 300 nM or less, about 250 nM or less, about 200 nM or less, about 150 nM or less, about 100 nM or less, about 90 nM or less, about 80 nM or less, about 70 nM or less, about 60 nM or less, about 50 nM or less, about 40 nM or less, about 30 nM or less, about 25 nM or less, about 20 nM or less, about 10 nM or less, about 1 nM or less, about 0.1 nM or less, etc.). D In some embodiments, the antibody or antigen-binding fragment binds to human, cynomolgus monkey, mouse, rat, and / or dog CTLA4 with a K of about 350 nM or less. D In some embodiments, the antibody or antigen-binding fragment binds with a K of about 100 nM or less. D In some embodiments, the antibody or antigen-binding fragment binds to human CTLA4 with a K of about 50 nM or less. D In some embodiments, the antibody or antigen-binding fragment binds to human CTLA4 with a K of about 10 nM or less. D Binds to human CTLA4 at K D Methods for measuring K can be performed using any method known in the art, including, for example, by surface plasmon resonance, ELISA, isothermal titration calorimetry, filter binding assay, EMSA, etc. In some embodiments, K D is measured by surface plasmon resonance or ELISA (see, for example, Example 3 below).

[0099] In some embodiments, the antibodies or antigen-binding fragments described herein have antagonist activity against human CTLA4. In some embodiments, the antibodies or antigen-binding fragments inhibit one or more activities of human CTLA4 (e.g., CTLA4 blockade as measured by an increase in reporter gene signal using a CTLA4 blockade reporter gene assay) when cells expressing human CTLA4 (e.g., human cells) are contacted by the antibody or antigen-binding fragment.

[0100] In some embodiments, the antibody or antigen-binding fragment is cross-reactive with monkey (e.g., cynomolgus), mouse, rat, and / or dog CTLA4. In some embodiments, the antibody or antigen-binding fragment is cross-reactive with monkey CTLA4. In some embodiments, the antibody or antigen-binding fragment is cross-reactive with mouse CTLA4. In some embodiments, the antibody or antigen-binding fragment is cross-reactive with rat CTLA4. In some embodiments, the antibody or antigen-binding fragment is cross-reactive with dog CTLA4. In some embodiments, the antibody or antigen-binding fragment is cross-reactive with monkey and mouse CTLA4; monkey and rat CTLA4; monkey and dog CTLA4; mouse and rat CTLA4; mouse and dog CTLA4; rat and dog CTLA4; monkey, mouse, and rat CTLA4; monkey, rat, and dog CTLA4; mouse, rat, and dog CTLA4; or monkey, mouse, rat, and dog CTLA4. In some embodiments, an antibody or antigen-binding fragment is cross-reactive if the antibody or antigen-binding fragment binds to a non-human CTLA4 molecule with a KD of less than about 500 nM (e.g., less than about 1 nM, less than about 10 nM, less than about 25 nM, less than about 50 nM, less than about 75 nM, less than about 100 nM, less than about 150 nM, less than about 200 nM, less than about 250 nM, less than about 300 nM, less than about 350 nM, etc.). Methods for measuring antibody cross-reactivity are known in the art and include, but are not limited to, surface plasmon resonance, ELISA, isothermal titration calorimetry, filter binding assays, EMSA, etc. In some embodiments, cross-reactivity is measured by ELISA.

[0101] In some embodiments, the antibody induces an ADCC effect against CTLA4-expressing cells (e.g., against CTLA4-expressing human cells, such as Tregs) after the antibody binds to the cell-expressed CTLA4. Methods (e.g., in vitro methods) for measuring ADCC effect are well known in the art. In some embodiments, the antibody induces an ADCC effect of greater than about 10% compared to a control (e.g., an isotype control or ipilimumab) (e.g., induces ADCC by greater than about 10%, greater than about 15%, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, etc.).

[0102] In some embodiments, the antibody or antigen-binding fragment can inhibit tumor cell growth and / or proliferation. In some embodiments, tumor cell growth and / or proliferation is inhibited by at least about 5% (e.g., at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 99%) when contacted with the antibody or antigen-binding fragment, compared to corresponding tumor cells not contacted with the antibody or antigen-binding fragment (or compared to corresponding tumor cells contacted with an isotype control antibody). In some embodiments, the antibody or antigen-binding fragment can reduce tumor volume in a subject when the antibody or antigen-binding fragment is administered to the subject. In some embodiments, the antibody or antigen-binding fragment can reduce tumor volume in a subject by at least about 5% (e.g., at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 99%) compared to the initial tumor volume in the subject (e.g., compared to a corresponding tumor in a subject administered an isotype control antibody prior to administration of the antibody or antigen-binding fragment). Methods for measuring tumor cell growth / proliferation, tumor volume, and / or tumor inhibition are known in the art.

[0103] In some embodiments, the antibody or antigen-binding fragment has a therapeutic effect against cancer. In some embodiments, the antibody or antigen-binding fragment alleviates one or more signs or symptoms of cancer. In some embodiments, a subject suffering from cancer experiences a partial or complete remission when administered the antibody or antigen-binding fragment.

[0104] In another aspect, the present disclosure provides isolated antibodies that compete or cross-compete with any of the exemplary antibodies of the present disclosure, e.g., TY21585, TY21586, TY21587, TY21588, TY21589, TY21580, TY21591, TY21686, TY21687, TY21689, TY21680, TY21691, and / or TY21692, for binding to human CTLA4. In certain embodiments, the present application provides isolated antibodies that compete or cross-compete with any of the exemplary antibodies of the present disclosure for binding to the same epitope on human CTLA4. The ability of an antibody to compete or cross-compete for binding with another antibody can be determined using standard binding assays known in the art, such as BIAcore analysis, ELISA assays, or flow cytometry. For example, an exemplary antibody of the present disclosure can be allowed to bind to human CTLA4 under saturating conditions, and then the ability of a test antibody to bind to CTLA4 can be measured. If the test antibody can bind to CTLA4 simultaneously with the exemplary antibody, the test antibody binds to a different epitope than the exemplary antibody. However, if the test antibody cannot bind to CTLA4 simultaneously, the test antibody binds to the same epitope, an overlapping epitope, or an epitope that is very close to the epitope bound by the exemplary antibody. This experiment can be performed using a variety of methods, such as ELISA, RIA, FACS, or surface plasmon resonance.

[0105] In some embodiments, the antibody or antigen-binding fragment blocks the binding between CTLA4 and one or more of its binding partners (e.g., human CTLA4 and human CD80, human CTLA4 and human CD86). In some embodiments, the antibody or antigen-binding fragment blocks the binding between CTLA4 and its ligand in vitro. In some embodiments, the antibody or antigen-binding fragment has a half maximal inhibitory concentration (IC) of about 500 nM or less (e.g., about 500 nM or less, about 400 nM or less, about 300 nM or less, about 200 nM or less, about 100 nM or less, about 50 nM or less, about 25 nM or less, about 10 nM or less, about 1 nM or less, etc.) for blocking CTLA4 binding to CD80 and / or CD86. 50 In some embodiments, the antibody or antigen-binding fragment has a half maximal inhibitory concentration (IC) of about 100 nM or less for blocking CTLA4 binding to CD80 and / or CD86. 50 ). In some embodiments, the antibody or antigen-binding fragment completely blocks the binding of human CTLA4 to CD80 and / or CD86 when provided at a concentration of about 100 nM or greater (e.g., about 100 nM or greater, about 500 nM or greater, about 1 μM or greater, about 10 μM or greater, etc.). As used herein, the term "complete blocking" or "completely blocks" refers to the ability of an antibody or antigen-binding fragment to reduce binding between a first protein and a second protein by at least about 80% (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 99%, etc.). Methods for measuring the ability of an antibody or antigen-binding fragment to block binding of a first protein (e.g., human CTLA4) and a second protein (e.g., human CD80 or human CD86) are known in the art and include, but are not limited to, by BIAcore analysis, ELISA assay, and flow cytometry. In some embodiments, the anti-CTLA4 antibodies described herein have less activity in blocking ligand binding than ipilimumab.

[0106] In some embodiments, the anti-CTLA4 antibody has a K of 1000 nM or less (e.g., 50 nM or less, 10 nM or less) as measured by surface plasmon resonance. D In some embodiments, the antibody is cross-reactive with at least one non-human species selected from cynomolgus monkey, mouse, rat, and dog.

[0107] In some embodiments, the anti-CTLA4 antibody specifically binds to an epitope similar to the ligand binding site of human CTLA4. In some embodiments, the antibody specifically binds to an epitope similar to the CD80 binding site of human CTLA4. In some embodiments, the antibody specifically binds to an epitope similar to the CD86 binding site of human CTLA4. In some embodiments, the antibody specifically binds to an epitope comprising one or more amino acid residues in the ligand binding site of human CTLA4 (e.g., the CD80 and / or CD86 binding site). In some embodiments, the antibody specifically binds to an epitope on human CTLA4 that is distinct from the epitope of ipilimumab. In some embodiments, the epitope does not include amino acid residues in the CC' loop motif of human CTLA4. In some embodiments, the epitope does not include amino acid residues L106 or I108 of human CTLA4. In some embodiments, the antibody specifically binds to an epitope comprising amino acid residues Y105 and L106 but not I108 of human CTLA4, where the numbering of the amino acid residues is based on the following sequence: KAMHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPE (SEQ ID NO: 108).

[0108] In some embodiments, the anti-CTLA4 antibody comprises a heavy chain variable region and a light chain variable region, wherein a) the heavy chain variable region comprises HVR-H1, HVR-H2, and HVR-H3, and HVR-H1 is selected from the group consisting of Formula (I): X1TFSX2YX3IHWV (SEQ ID NO: 1), where X1 is F or Y, X2 is D or G, and X3 is A, G, or W; Formula (II): YSIX1SGX2X3WX4WI (SEQ ID NO: 2), where X1 is S or T, X2 is H or Y, X3 is H or Y, and X4 is A, D, or S; and Formula (I II):FSLSTGGVAVX1WI (SEQ ID NO: 3) (wherein X1 is G or S), and HVR-H2 comprises an amino acid sequence according to a formula selected from formula (IV):IGX1IX2HSGSTYYSX3SLKSRV (SEQ ID NO: 4) (wherein X1 is D or E, X2 is S or Y, and X3 is P or Q), formula (V):IGX1ISPSX2GX3TX4YAQKFQGRV (SEQ ID NO: 5) (wherein X1 is I or W, X2 is G or S, X3 is G or S, and X4 is K or N), and formula (VI):V X1 is G, R, or S, X2 is S or Y, X3 is G, or S, and X4 is S or T; and HVR-H3 comprises an amino acid sequence according to a formula selected from formula (VII): ARX1X2X3X4FDX5 (SEQ ID NO: 7) (wherein X1 is G, R, or S, X2 is A, I, or Y, X3 is D, V, or Y, X4 is A, E, or Y, and X5 is I or Y), formula (VIII): ARX1GX2GYFDX3 (SEQ ID NO: 8) (wherein X1 is A, G, or S, X2 is S or Y, X3 is G or S, and X4 is S or T). column number 8) (wherein X1 is D or L, X2 is F or Y, and X3 is V or Y), formula (IX): ARX1X2X3X4AX5X6FDY (SEQ ID NO: 9) (wherein X1 is L or R, X2 is I or P, X3 is A or Y, X4 is S or T, X5 is T or Y, and X6 is A or Y), and formula (X): ARDX1X2X3GSSGYYX4GFDX5 (SEQ ID NO: 10) (wherein X1 is I or V, X2 is A or H, X3 is P or S, and X4 is D or Y,and X5 is F or V), and / or b) the light chain variable region comprises HVR-L1, HVR-L2, and HVR-L3, wherein HVR-L1 is selected from the group consisting of formula (XI): RASQX1X2X3SX4LX5 (SEQ ID NO: 11) (wherein X1 is G or S, X2 is I or V, X3 is G or S, X4 is S or Y, and X5 is A or N), formula (XII): RASQX1VX2X3RX4LA (SEQ ID NO: 12) (wherein X1 is G or S, X2 is I or V, X3 is G or S, X4 is S or Y, and X5 is A or N), wherein X1 is S or T, X2 is F, R, or S, X3 is G or S, and X4 is F or Y), and formula (XIII): RASX1SVDFX2GX3SFLX4 (SEQ ID NO: 13) (wherein X1 is E or Q, X2 is D, F, H, or Y, X3 is F, I, or K, and X4 is A, D, or H); and HVR-L2 comprises an amino acid sequence according to a formula selected from formula (XIV): X1ASX2X3X4X5GX6 (SEQ ID NO: No. 14) (wherein Xi is A or D, X2 is N, S, or T, X3 is L or R, X4 is A, E, or Q, X5 is S or T, and X6 is I or V); and HVR-L3 comprises an amino acid sequence according to formula (XV): YCX1X2X3X4X5X6PX7T (SEQ ID NO: 15) (wherein Xi is E, Q, or V, X2 is H or Q, X3 is A, G, H, R, or S, X4 is D, L, S, or Y, and X5 is E). , G, P, Q, or S, X6 is L, T, V, or W, and X7 is F, L, P, W, or Y), formula (XVI): YCQQX1X2X3WPPWT (SEQ ID NO: 16) (wherein X1 is S or Y, X2 is D or Y, and X3 is Q or Y), and formula (XVII): YCQX1YX2SSPPX3YT (SEQ ID NO: 17) (wherein X1 is H or Q, X2 is T or V, and X3 is E or V).

[0109] In some embodiments, the antibody comprises (a) HVR-H1 comprising an amino acid sequence selected from SEQ ID NOs: 18-29, HVR-H2 comprising an amino acid sequence selected from SEQ ID NOs: 30-39, and HVR-H3 comprising an amino acid sequence selected from SEQ ID NOs: 40-52, and / or (b) HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs: 53-65, HVR-L2 comprising an amino acid sequence selected from SEQ ID NOs: 66-69, and HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 70-81. In some embodiments, the antibody comprises one, two, three, four, five, or all six of the HVRs set forth for any of the exemplary antibodies described in Table A below.

[0110] TIFF2025529121000002.tif255168

[0111] TIFF2025529121000003.tif75170

[0112] In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 18, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 40, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 53, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 70. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 19, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 31, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 54, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 71. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 42, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 55, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 72. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 21, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 43, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 56, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 73. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 22, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 34, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 44, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 74. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 23, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 45, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 58, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 75.In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 24, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 46, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 59, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 76. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 36, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 47, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 60, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 69, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 77. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 26, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 37, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 48, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 78. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 27, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 32, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 49, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 62, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 79. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 28, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 37, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 50, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 63, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 80. In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 18, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 38, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 51, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 64, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 81.In some embodiments, the antibody comprises HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, HVR-H2 comprising the amino acid sequence of SEQ ID NO: 39, HVR-H3 comprising the amino acid sequence of SEQ ID NO: 52, HVR-L1 comprising the amino acid sequence of SEQ ID NO: 65, HVR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 77.

[0113] In some embodiments, the antibody comprises a) a heavy chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 82-94, and / or b) a light chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 95-107. In some embodiments, the antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to a sequence selected from SEQ ID NOs: 82-94, and / or a light chain variable region comprising an amino acid sequence having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) sequence identity to a sequence selected from SEQ ID NOs: 95-107. In some embodiments, the antibody comprises the heavy chain variable region and light chain variable region of any of the exemplary antibodies set forth in Table B below. In some embodiments, the antibody comprises one, two, or all three HVRs of the heavy chain variable region and / or one, two, or all three HVRs of the light chain variable region set forth for any of the exemplary antibodies set forth in Table B below.

[0114] TIFF2025529121000004.tif255165

[0115] TIFF2025529121000005.tif114170

[0116] In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 82 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 96. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 84 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 97. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 85 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 98. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 86 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 99. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 88 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 101. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 102. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 90 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 91 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 104. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 92 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 105. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 93 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 106. In some embodiments, the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 94 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 107.

[0117] In some embodiments, an antibody of the present application cross-competes for binding to human CTLA4 with an antibody comprising (a) an HVR-H1 comprising an amino acid sequence selected from SEQ ID NOs: 18-29, an HVR-H2 comprising an amino acid sequence selected from SEQ ID NOs: 30-39, and an HVR-H3 comprising an amino acid sequence selected from SEQ ID NOs: 40-52, and / or (b) an HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs: 53-65, an HVR-L2 comprising an amino acid sequence selected from SEQ ID NOs: 66-69, and an HVR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 70-81. In some embodiments, an antibody of the present application cross-competes for binding to human CTLA4 with an antibody comprising one, two, three, four, five, or all six of the HVRs set forth for any of the exemplary antibodies described in Table A. In some embodiments, an antibody of the present application cross-competes for binding to human CTLA4 with an antibody comprising a) a heavy chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 82-94, and / or b) a light chain variable region comprising an amino acid sequence selected from SEQ ID NOs: 95-107. In some embodiments, an antibody of the present application cross-competes for binding to human CTLA4 with an antibody comprising the VH and / or VL shown for any of the exemplary antibodies described in Table B.

[0118] The CTLA4 antibodies described herein can be of any class, such as IgG, IgM, IgE, IgA, or IgD. In some embodiments, the CTLA4 antibody is of an IgG class, such as an IgG1, IgG2, IgG3, or IgG4 subclass. CTLA4 antibodies can be converted from one class or subclass to another using methods known in the art. An exemplary method for producing antibodies of a desired class or subclass is to isolate nucleic acids encoding the heavy chain of a CTLA4 antibody and nucleic acids encoding the light chain of a CTLA4 antibody, and then convert the nucleic acids to V. H The sequence encoding the V HThe method includes linking the sequence to a sequence encoding a heavy chain constant region of the desired class or subclass, expressing the light chain gene and heavy chain construct in a cell, and collecting the CTLA4 antibody. The antibodies of the present application can be monoclonal or polyclonal. The antibodies of the present application can be monospecific or multispecific (e.g., bispecific, trispecific, etc.) antibodies. In some embodiments, the CTLA4 antibodies described herein can contain one or more Fc mutations (e.g., that modulate (increase or decrease) ADCC or CDC activity). Any suitable Fc mutation known in the art can be used in the CTLA4 antibodies of the present application.

[0119] In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 127).In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGYSISSGYHWSWIRQAPGKGLEWLARIDWDDDKYYSTSLKSRLTISRDNSKNTLYLQLNSLRAEDTAVYYCARSYVYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVRGRFLAWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSSSWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 127). In some embodiments, anti-CTLA4 antibodies refer to a mixture of antibody species, each antibody species comprising a light chain comprising the amino acid sequence of SEQ ID NO: 127 and a heavy chain comprising the amino acid sequence of either SEQ ID NO: 125 or 126.

[0120] In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAIHWVRQAPGKGLEWIGIISPSGGSTKYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARLGYGYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVDFYGISFLHWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVQALQLPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 130).In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSDYAIHWVRQAPGKGLEWIGIISPSGGSTKYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARLGYGYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVDFYGISFLHWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVQALQLPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 130). In some embodiments, anti-CTLA4 antibodies refer to a mixture of antibody species, each antibody species comprising a light chain comprising the amino acid sequence of SEQ ID NO: 130 and a heavy chain comprising the amino acid sequence of either SEQ ID NO: 128 or 129.

[0121] In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGYSITSGYYWAWIRQAPGKGLEWVSSISGSGSTTYYADSVKGRFTISRDNSKNTLYLQLNSLRAEDTAVYYCARDGFGYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCSASSSVSYVYWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVQGLQTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 133).In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGYSITSGYYWAWIRQAPGKGLEWVSSISGSGSTTYYADSVKGRFTISRDNSKNTLYLQLNSLRAEDTAVYYCARDGFGYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTI and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCSASSSVSYVYWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCVQGLQTPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 133). In some embodiments, anti-CTLA4 antibodies refer to a mixture of antibody species, each antibody species comprising a light chain comprising the amino acid sequence of SEQ ID NO: 133 and a heavy chain comprising the amino acid sequence of either SEQ ID NO: 131 or 132.

[0122] In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYAIHWVRQAPGKGLEWIGIISPSGGGTKYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARHPFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVDFYGISFLDWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYVSSPPEYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 136).In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGFTFSGYAIHWVRQAPGKGLEWIGIISPSGGGTKYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARHPFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVDFYGISFLDWYQQKPGKAPKLLIYDASNRATGIPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYVSSPPEYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 136). In some embodiments, anti-CTLA4 antibodies refer to a mixture of antibody species, each antibody species comprising a light chain comprising the amino acid sequence of SEQ ID NO: 136 and a heavy chain comprising the amino acid sequence of either SEQ ID NO: 134 or 135.

[0123] In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGYTFSGYAIHWVRQAPGKGLEWIGIISPSGGGTKYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARLYDVAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVDFHGKSFLHWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCEQSLEVPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 139).In some embodiments, the anti-CTLA4 antibody has the amino acid sequence EVQLVESGGGLVQPGGSLRLSCAASGYTFSGYAIHWVRQAPGKGLEWIGIISPSGGGTKYAQKFQGRVTISRDNSKNTLYLQLNSLRAEDTAVYYCARLYDVAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK and a light chain comprising the amino acid sequence DIQLTQSPSSLSASVGDRVTITCRASQSVDFHGKSFLHWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCEQSLEVPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 139). In some embodiments, anti-CTLA4 antibodies refer to a mixture of antibody species, each antibody species comprising a light chain comprising the amino acid sequence of SEQ ID NO: 139 and a heavy chain comprising the amino acid sequence of either SEQ ID NO: 137 or 138.

[0124] In some embodiments, the anti-CTLA4 antibody is an antigen-binding fragment of an anti-CTLA4 antibody. The antigen-binding fragment of an anti-CTLA4 antibody comprises: (i) V L , V H , C L , and C H(ii) a Fab fragment, which is a monovalent fragment consisting of one domain; (iii) a F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; and (iv) a V H and C H (iv) a single-arm V of an antibody; L and V H Fv fragment consisting of domains, (v) V H (vi) isolated CDRs, and (vii) antibody V domains. H V of antibody linked to domain L and single-chain antibodies (scFv), which are polypeptides comprising a region (see, e.g., Bird et al. (1988) Science 242:423-426; Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883).

[0125] In some embodiments, the anti-CTLA4 antibody is a derivative of any one of the anti-CTLA4 antibodies described herein. In some embodiments, the antibody derivative is derived from an exemplary antibody of the present application (e.g., a "parent antibody") by modifying the amino acid sequence while preserving the overall molecular structure of the amino acid sequence of the parent antibody. The amino acid sequence of any region of the parent antibody chain, such as the framework region, HVR region, or constant region, may be modified. Types of modifications include substitution, insertion, deletion, or a combination thereof, of one or more amino acids of the parent antibody.

[0126] In some embodiments, the antibody derivative comprises a VL or VH region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 82-107. In some embodiments, the antibody derivative comprises an HVR-H1 amino acid sequence region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 18-29. In some embodiments, the antibody derivative comprises an HVR-H2 amino acid sequence region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 30-39. In some embodiments, the antibody derivative comprises an HVR-H3 amino acid sequence region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 40-52. In some embodiments, the antibody derivative comprises an HVR-L1 amino acid sequence region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 53-65.In some embodiments, the antibody derivative comprises an HVR-L2 amino acid sequence region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 66-69. In some embodiments, the antibody derivative comprises an HVR-L3 amino acid sequence region that is at least 65%, at least 75%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in any of SEQ ID NOs: 70-81.

[0127] In some particular embodiments, the derivative comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 conservative or non-conservative substitutions and / or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 additions and / or deletions to the amino acid sequence set forth in any of SEQ ID NOs: 18-107.

[0128] Amino acid substitutions include both conservative and non-conservative substitutions. The term "conservative amino acid substitution" refers to the replacement of one amino acid with another when the two amino acids have similarities in certain physicochemical properties, such as polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or the amphipathicity of related residues. For example, substitutions can typically be made within the following groups: (a) nonpolar (hydrophobic) amino acids such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; (b) polar neutral amino acids such as glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids such as arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids such as aspartic acid and glutamic acid.

[0129] Modifications may be made at any position in the antibody amino acid sequence, including the HVR, framework region, or constant region. In one embodiment, the present application provides antibody derivatives that contain the VH and VL HVR sequences of the exemplary antibodies of the present disclosure, but contain framework sequences that differ from those of the exemplary antibodies. Such framework sequences can be obtained from public DNA databases or published references that contain germline antibody gene sequences. For example, germline DNA sequences of human heavy and light chain variable region genes can be found in the Genbank database or the "VBase" human germline sequence database (Kaba et al., Sequences of Proteins of Immunological Interest, Fifth Edition, USDapartment of Health and Human Services, NIH Publication No. 91-3242 (1991); Tomlinson et al., J. Mol. Biol. 227:776-798 (1992); and Cox et al., Eur. J. Immunol. 24:827-836 (1994)). Framework sequences that can be used in constructing antibody derivatives include those that are structurally similar to the framework sequences used by the exemplary antibodies of the present disclosure. For example, the HVR-H1, HVR-H2, and HVR-H3 sequences, and the HVR-L1, HVR-L2, and HVR-L3 sequences of the exemplary antibodies can be grafted into framework regions having sequences identical to those found in the germline immunoglobulin gene from which the framework sequences are derived, or the HVR sequences can be grafted into framework regions containing one or more mutations compared to the germline sequences.

[0130] In some embodiments, the antibody derivative is a chimeric antibody comprising the amino acid sequence of an exemplary antibody of the present disclosure. In one example, one or more HVRs from one or more exemplary antibodies are combined with HVRs from an antibody from a non-human animal, such as a mouse or rat. In another example, all HVRs of the chimeric antibody are derived from one or more exemplary antibodies. In some specific embodiments, the chimeric antibody comprises one, two, or three HVRs from the heavy chain variable region and / or one, two, or three HVRs from the light chain variable region of an exemplary antibody. Chimeric antibodies can be generated using conventional methods known in the art.

[0131] Another type of modification is the V H and / or V L The preferred method involves mutating amino acid residues within the HVR regions of the heavy and / or light chains. Site-directed mutagenesis or PCR-mediated mutagenesis can be used to introduce the mutation(s), and the effect on antibody binding or other desired functional properties can be assessed using in vitro or in vivo assays known in the art. Typically, conservative substitutions are introduced. The mutations can be amino acid additions and / or deletions. Furthermore, typically, no more than one, two, three, four, or five residues within the HVR regions are altered. In some embodiments, the antibody derivative contains one, two, three, or four amino acid substitutions in the heavy and / or light chain HVRs. In another embodiment, the amino acid substitutions involve changing one or more cysteines in the antibody to another residue, such as, but not limited to, alanine or serine. The cysteines can be standard or non-standard cysteines. In one embodiment, the antibody derivative has one, two, three, or four conservative amino acid substitutions in the heavy chain HVR regions compared to the amino acid sequence of an exemplary antibody.

[0132] Modifications can also be made to framework residues within the VH and / or VL regions. Typically, such framework variants are made to reduce the immunogenicity of antibodies. One approach is to "backmutate" one or more framework residues to the corresponding germline sequence. An antibody that has undergone somatic mutation may contain framework residues that differ from the germline sequence from which the antibody is derived. Such residues can be identified by comparing the antibody framework sequence with the germline sequence from which the antibody is derived. To return the framework region sequences to their germline configuration, somatic mutations can be "backmutated" to the germline sequence, for example, by site-directed mutagenesis or PCR-mediated mutagenesis.

[0133] Furthermore, modifications can also be made within the Fc region of exemplary antibodies, typically altering one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and / or antigen-dependent cellular cytotoxicity. In one example, the hinge region of CH1 is modified to alter, e.g., increase or decrease, the number of cysteine ​​residues in the hinge region. This approach is further described in U.S. Patent No. 5,677,425. The number of cysteine ​​residues in the hinge region of CH1 is altered, for example, to facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody. In another case, the Fc hinge region of an antibody is mutated to decrease the biological half-life of the antibody.

[0134] Furthermore, the antibodies of the present application can be modified to alter their potential glycosylation sites or patterns, according to routine experimentation known in the art. In another aspect, the present application provides derivatives of CTLA4 antibodies containing at least one mutation in the variable region of the light or heavy chain that alters the glycosylation pattern in the variable region. Such antibody derivatives may have increased affinity and / or altered specificity for antigen binding. The mutations may add a new glycosylation site to the V region, change the position of one or more V region glycosylation site(s), or remove an existing V region glycosylation site. In one embodiment, the present application provides a derivative of a CTLA4 antibody with a potential N-linked glycosylation site at an asparagine in the heavy chain variable region, thereby eliminating a potential N-linked glycosylation site in one heavy chain variable region. In another embodiment, the present application provides a derivative of a CTLA4 antibody with a potential N-linked glycosylation site at an asparagine in the heavy chain variable region, thereby eliminating a potential N-linked glycosylation site in both heavy chain variable regions. Methods for altering the glycosylation pattern of antibodies are known in the art and are described, for example, in US Pat. No. 6,933,368, the disclosure of which is incorporated herein by reference.

[0135] IV. Pharmaceutical Compositions, Kits and Articles of Manufacture In another aspect, the present application provides a composition comprising any one of the anti-CTLA4 antibodies described herein. In some embodiments, the composition is a pharmaceutical composition comprising an anti-CTLA4 antibody and a pharmaceutically acceptable carrier. The composition can be prepared by conventional methods known in the art.

[0136] The term "pharmaceutically acceptable carrier" refers to any inert substance suitable for use in a formulation for delivery of an active agent (e.g., an anti-CTLA4 antibody). Carriers can be antiadherents, binders, coatings, disintegrants, fillers or diluents, preservatives (such as antioxidants, antibacterial agents, or antifungal agents), sweeteners, absorption delaying agents, wetting agents, emulsifiers, buffers, etc. Examples of suitable pharmaceutically acceptable carriers include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.), dextrose, vegetable oils (e.g., olive oil), saline, buffers, buffered saline, and isotonic agents, such as sugars, polyalcohols, sorbitol, and sodium chloride. The composition can be in any suitable dosage form, including liquid, semisolid, and solid dosage forms. Examples of liquid dosage forms include solutions (e.g., injectable and infusible solutions), microemulsions, liposomes, dispersions, or suspensions. Examples of solid dosage forms include tablets, pills, capsules, microcapsules, and powders. A specific form of the composition suitable for delivering anti-CTLA4 antibodies is a sterile liquid, such as a solution, suspension, or dispersion for injection or infusion. Sterile solutions can be prepared by incorporating the required amount of antibody into a suitable carrier, followed by sterile microfiltration. Generally, dispersions are prepared by adding antibody to a sterile solvent containing a basic dispersion medium and other carriers. For sterile powders for preparing sterile liquids, preparation methods include vacuum drying and freeze-drying (lyophilization) to obtain a powder containing the active ingredient and any additional desired ingredients from its previously sterile-filtered solution. Various dosage forms of the composition can be prepared by conventional techniques known in the art.

[0137] The relative amount of anti-CTLA4 antibody included in the composition will vary depending on many factors, including the particular anti-CTLA4 antibody and carrier used, the dosage form, and the desired release and pharmacodynamic properties. The amount of anti-CTLA4 antibody in a single dosage form will generally be that amount that produces a therapeutic effect, although lower amounts may also be used. Typically, this amount ranges from about 0.01 percent to about 99 percent, from about 0.1 percent to about 70 percent, or from about 1 percent to about 30 percent, based on the total weight of the dosage form.

[0138] In addition to the anti-CTLA4 antibody, one or more additional therapeutic agents can be included in the composition. Examples of additional therapeutic agents are described in the "Methods of Treatment" section of this specification. The appropriate amount of additional therapeutic agent to be included in the composition can be easily selected by those skilled in the art and will vary depending on many factors, such as the specific drug and carrier used, the dosage form, and the desired release and pharmacodynamic properties. The amount of additional therapeutic agent included in a single dosage form is generally the amount of drug that produces a therapeutic effect, but may be a smaller amount.

[0139] In some embodiments, an article of manufacture containing a substance useful for treating cancer is provided. The article of manufacture can include a container and a label or package insert on or attached to the container. Suitable containers include, for example, bottles, vials, syringes, and the like. The container can be formed from a variety of materials, such as glass or plastic. Generally, the container holds a composition effective for treating cancer as described herein and can have a sterile access port (e.g., the container is an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle). Package insert refers to information typically included in commercial packaging for therapeutic products, including directions, usage, dosage, administration, contraindications, and / or warnings regarding the use of the therapeutic product. In some embodiments, the package insert indicates that the composition is used for treating cancer. The label or package insert can further include instructions for administering the composition to a patient.

[0140] The article of manufacture may further comprise a second container containing a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution, and dextrose solution. The article of manufacture may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0141] Also provided are kits useful for various purposes, such as, for example, treating cancer as described herein, optionally in combination with an article of manufacture. The kits of the present application include one or more containers containing any one of the compositions (or unit dosage forms and / or articles of manufacture) described herein. In some embodiments, the kits further include other agents (e.g., one or more additional therapeutic agents) and / or instructions for use in accordance with any of the methods described herein. The kits may further include instructions for individual selection of appropriate treatments. The instructions provided in the kits of the present application are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), although machine-readable instructions (e.g., instructions transferred to a magnetic or optical storage disk) are also acceptable.

[0142] For example, in some embodiments, a kit is provided that includes a pharmaceutical composition comprising any one of the anti-CTLA4 antibodies described herein and a pharmaceutically acceptable carrier, and instructions for administering the pharmaceutical composition to a subject with cancer. In some embodiments, the kit includes a pharmaceutical composition that includes an additional therapeutic agent, such as a chemotherapeutic agent. In some embodiments, the kit includes a kit that includes one or more biomarkers described herein (e.g., CD8+ T cells, CD4+ T cells, CD8 ... em cells, CD4+T em cell, T reg cells, CD8+T em Cells and T reg Ratio to CD4+T cells em Cells and T reg The present invention includes assays and reagents for determining levels of NK cells (NK cells, NK cells, and B cells) and their ratios.

[0143] The kits of the present application are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like. The kits may optionally provide additional components, such as buffers and instructional information. Thus, the present application also provides articles of manufacture that include vials (such as sealed vials), bottles, jars, flexible packaging, and the like.

[0144] The containers may be unit doses, bulk packages (e.g., multi-dose packages), or sub-unit doses. The kits may also include multiple unit doses of the pharmaceutical composition and instructions for use, and may be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies and compounding pharmacies). [Example]

[0145] The present invention may be further understood by reference to the following examples, which are provided by way of illustration and are not intended to be limiting.

[0146] Example 1. A Phase 1b, Open-Label, Dose-Escalation Study of TY21580 and the Combination of TY21580 and Toripalimab (Anti-PD-1 Antibody) in Patients with Advanced / Metastatic Solid Tumors

[0147] The following example describes an ongoing Phase Ib clinical trial to evaluate the safety and tolerability of TY21580 monotherapy and TY21580 in combination with toripalimab (see ClinicalTrials.gov Identifier: NCT04501276).

[0148] Objectives: The primary objectives of this study are to evaluate the safety and tolerability of TY21580 administered intravenously (IV) in an escalating dose schedule, alone and in combination with toripalimab, in adult patients with advanced / metastatic solid tumors, to determine the maximum tolerated dose (MTD) of TY21580 alone and in combination with toripalimab, and to determine the recommended phase 2 dose (RP2D). The secondary objectives of this study are to evaluate the pharmacokinetic (PK) profile of TY21580 in monotherapy or in combination with toripalimab; to assess the dose proportionality of key PK parameters of TY21580 (e.g., area under the time-concentration curve [AUC], maximum plasma concentration [Cmax]); to evaluate the immunogenicity of TY21580 in monotherapy or in combination with toripalimab; to characterize the relationship between TY21580 immunogenicity (anti-drug antibody [ADA] positivity rate) and TY21580 PK, safety, and efficacy parameters; and to evaluate the preliminary antitumor activity of TY21580 in monotherapy and combination therapy.

[0149] Methods: This is a phase 1b / 2, open-label, dose-escalation study of TY21580 monotherapy and TY21580 in combination with toripalimab in patients with advanced / metastatic solid tumors. The expected total number of patients will be up to approximately 82 patients. The dose escalation will consist of two parts. Part A - TY21580 monotherapy dose escalation every 3 weeks (Q3W). Part B - TY21580 Q3W dose escalation in combination with toripalimab 240 mg Q3W.

[0150] Treatment cycles are 21 days long, with one IV dose of TY21580 and the combination of TY21580 and toripalimab administered on day 1 of the cycle. For patients receiving the TY21580-toripalimab combination, toripalimab will be administered approximately 30 minutes (±5 minutes) after the completion of the TY21580 IV infusion. The number of TY21580 treatment cycles may be adjusted based on emerging safety and PK / PD (e.g., biomarker, efficacy) data. DLTs will be evaluated by the SRC after all patients enrolled at a dose level have been followed for at least 21 days after the first dose of a specific regimen (the DLT observation period). During the study, patients will be evaluated for safety and toxicity, PK, immunogenicity, ORR, DOR, PFS, OS, and pre-specified biomarkers per the protocol.

[0151] Part A (TY21580 monotherapy dose escalation) will employ an accelerated titration design (ATD) at the lower dose levels (DL1 and DL2), followed by a traditional 3+3 dose escalation or mTPI design at the higher dose levels until the RP2D is determined, starting at DL1 (0.003 mg / kg).

[0152] The study will be conducted using 10 potential dose levels administered by IV infusion, as shown in Table 1. TIFF2025529121000006.tif77170 * The proposed dose, schedule, and PK time points may be revisited and modified during the study based on safety data and observed systemic exposure, and as determined by the SRC. DL-1 is a lower titration dose used if a DLT is observed or if a clinically significant Grade 2 or higher toxic AE is observed at DL1. ** If one patient experiences a DLT or two cases of Grade 2 or higher drug-related toxicity during the 21-day DLT evaluation period, additional patients will be enrolled and the traditional 3+3 dose escalation criteria will apply to that dose level, with all subsequent dose levels following the traditional 3+3 dose escalation criteria.

[0153] In the 2019 study, one patient will be treated per dose level. If a patient experiences DLT or two cases of grade 2 or higher drug-related toxicity (as agreed upon by the investigator and sponsor), the dose levels will be escalated according to a 3+3 design.

[0154] Dose escalation will follow a traditional 3 + 3 design from DL3 (0.03 mg / kg) onwards, with either 3 or 6 patients treated at each dose level depending on the incidence of DLT. Initially, 3 patients will be enrolled at that dose level, with a sentinel patient treated at least 24 hours before any subsequent patients.

[0155] For the TY21580-toripalimab combination regimen, a modified toxicity probability interval (mTPI) design with a target DLT rate of approximately 30% will be applied for dose escalation and confirmation to determine the RP2D for TY21580 in combination with toripalimab. Dose escalation will include the dose escalation cohorts shown in Table 2. TIFF2025529121000007.tif33170 a The SRC approved a starting dose of 6 mg / kg of TY21580 in the combination group. b DL3 is an option for the TY21580 + toripalimab combination.

[0156] The SRC approved a starting dose of 6 mg / kg for TY21580 in the combination group. Starting with the SRC-determined combination dose, dose escalation will continue at the next dose level (e.g., 10 mg / kg) depending on clearance of TY21580 monotherapy until the RP2D for the combination is determined. The maximum dose of TY21580 administered in combination with toripalimab will not exceed the RP2D determined for TY21580 monotherapy. If the starting dose (DL1) of TY21580 in the combination setting with toripalimab is deemed intolerable, a reduced dose (DL-1) of TY21580 is available. All dose escalation and deescalation decisions are based on the occurrence of DLTs. DLTs will be evaluated by the SRC after all patients enrolled in a dose level have been followed for at least 21 days after the first dose of a specific regimen (the DLT observation period). The medical monitor will be contacted and will review any adverse events, day 8 and day 15 labs obtained from the first patient as they become available.

[0157] The safety and tolerability of each dose level will be evaluated by the SRC after all patients enrolled at that dose level have been followed for at least 21 days (the DLT observation period) after the first dose of the TY21580-toriparimab combination therapy. Once either the MTD or the maximum administered dose (MAD) is reached, the RP2D will be determined. The RP2D will be defined based on the observation of the MTD in a dose-level cohort, or the MAD dose in the absence of an MTD or DLT observation. It will include dose levels below the MTD or MAD, or intermediate dose levels between pre-specified dose levels, based on an overall evaluation of all safety data, all available PK and pharmacodynamic data, and documented objective response observations. The RP2D will be the pharmacologically effective dose.

[0158] Patients who discontinue treatment due to intolerable AEs related to TY21580, TY21580 and toripalimab combination therapy will be followed until the AE returns to or stabilizes at grade 0 or 1, or until the patient receives new non-protocol treatment. The sponsor may decide to terminate the study at any time.

[0159] Investigational Drug, Dosage, and Administration. TY21580 will be administered IV over 60 to 90 minutes (±15 minutes) Q3W at the doses specified in Table 1 for monotherapy. Toripalimab will be administered at 240 mg every 3 weeks (Q3W) according to the package insert. For TY21580 and toripalimab combination therapy, toripalimab will be administered within 30 minutes (±5 minutes) after the end of the TY21580 infusion.

[0160] Duration of Treatment. If the investigator believes that continued treatment could benefit the patient, study treatment with monotherapy TY21580 (Q3W) or TY21580 combination regimens (each drug in either the TY21580-triparimumab regimen Q3W) will continue for up to 2 years, or until disease progression and / or unacceptable toxicity, or withdrawal of informed consent, whichever occurs first.

[0161] Safety Assessments. Safety assessments will be conducted during specific periodic physical examination findings, vital signs, ECOG performance status, laboratory variables (e.g., liver function tests / monitoring, hematology, coagulation tests, serum chemistry, urinalysis, and pregnancy test), ECG, and AEs. AEs will be graded according to NCI CTCAE v5.0. Investigator and site personnel are responsible for appropriate documentation and reporting of AEs / SAEs. Prior to dose escalation, the SRC will review safety data from the current level after all patients have completed the 21-day first cycle and determine whether escalation to the next dose level (or stop escalation) should continue. These decisions will be documented.

[0162] Efficacy Assessments. Tumor assessments for response / progression will be performed at baseline and every 6 weeks (± 1 week) for the first 12 weeks. Thereafter, assessments will be performed every 9 weeks (± 1 week) for the remainder of the treatment period until disease progression or death, treatment / study discontinuation due to treatment toxicity, loss to follow-up, withdrawal of consent, initiation of new cancer treatment, or study completion / exit, whichever occurs first. Exploratory efficacy assessments will be based on tumor assessment by the investigator according to RECIST v1.1 and / or iRECIST. All discontinued patients who received study drug will be included in the efficacy analysis of the intent-to-treat population. A subgroup exploratory analysis will be conducted among all discontinued patients who received at least one dose of TY21580 and had at least one tumor assessment performed.

[0163] Pharmacokinetic and immunogenicity assessment. Blood samples will be collected from all patients during the first cycle to measure serum concentrations of TY21580 and toripalimab in patients receiving the corresponding drugs. PK parameters will be monitored more intensively during the first treatment cycle. Starting with the second through fourth doses and every two cycles thereafter, if treatment continues beyond four cycles, serum concentrations of drug antibodies will be collected within 30 minutes before administration of the drug (trough) and at the end of the infusion. PK sampling time points can be adjusted based on cumulative data.

[0164] Blood samples for ADA against each drug antibody in matched drug-treated patients will be collected at pre-dose in cycles 1, 2, 3, and 4, and then every four cycles if treatment continues beyond four cycles. Additionally, ADA samples will be collected at the end of the study and the final follow-up visit, if possible. If ADA is positive, neutralizing activity will be assessed.

[0165] Monotherapy results

[0166] Interim results of the study are listed below.

[0167] General Observations

[0168] Forty-six patients were enrolled in the Phase 1b study and treated with TY21580 alone in different dose-escalation cohorts (i.e., 1 mg / kg, 3 mg / kg, 6 mg / kg, 10 mg / kg, 15 mg / kg). These patients included 10 ovarian / fallopian tube cancer, 6 pancreatic cancer, 5 mCRC, 4 renal cell carcinoma, 4 endometrial cancer, 2 melanoma, and 2 urothelial carcinoma. Other cancer types included soft tissue sarcoma, breast cancer, esophageal cancer, and HNSCC. The median age was 62 years, 62% had received ≥3 lines of prior therapy, and 31% had progressed after prior IO therapy.

[0169] Only one DLT (Grade (G) 4 hyperglycemia) was observed (10 mpk), and the MTD was not reached. Only three patients experienced Grade 3 or higher treatment-related AEs (TRAEs), with one patient reporting both Grade 3 and Grade 4; common TRAEs (>10%) were diarrhea, pruritus, and fatigue. Thirty-four patients underwent at least one tumor measurement after baseline, 10 had stable disease, and one patient with Kaposi's sarcoma (unrelated to HIV) achieved a PR.

[0170] TY21580 demonstrated a favorable safety and tolerability profile at doses up to 15 mg / kg (Tables 3 and 4). No MTD was observed at monotherapy up to 15 mg / kg Q3W, and only one DLT was observed at 10 mg / kg.

[0171] Significant increases in absolute T and N cell abundance and T regA reduction in the percentage of CTLA-4 cells correlates with favorable clinical outcomes. TY21580 has the potential to overcome the limitations of existing anti-CTLA-4 checkpoint inhibitors on the market and is predicted to extend their market potential beyond current anti-CTLA-4 inhibitors in both monotherapy and combination therapy settings. The anti-CTLA-4 therapy described herein may improve clinical benefit by expanding clonal diversity, infiltrating cold tumors, and treating patients who are resistant / refractory to current immunotherapies. Specific examples of the treatment of individual subjects in the study are described below. TIFF2025529121000008.tif64170TIFF2025529121000009.tif65170

[0172] Subject 1 A 74-year-old man with renal cell carcinoma who had relapsed on nivolumab was enrolled in the 10 mg / kg cohort. In this subject, CD8+ T cells increased after the first cycle of treatment (Figure 3), demonstrating that TY21580 is highly active in inducing T cell activation.

[0173] Subject 2 A 63-year-old white woman with clear cell carcinoma who underwent bilateral salpingo-oophorectomy was resistant to platinum-based chemotherapy. After four cycles of TY21580 monotherapy (6 mg / kg), the total size of the target lesions decreased at the next two tumor evaluations (Table 5).

[0174] Subject 3 A 77-year-old male with pancreatic cancer in the 10 mg / kg cohort who had received three prior lines of therapy had two target lesions, one in the pancreas and one in the liver, with baseline measurements of 35 mm for the pancreatic lesion and 15 mm for the liver lesion. After two cycles of TY21580 treatment, this patient underwent an initial tumor evaluation. This evaluation showed that the pancreatic lesion had shrunk to 29 mm and the liver lesion had shrunk to 10 mm, reflecting a 22% reduction in target lesion size (Table 5).

[0175] Subject 4 A 69-year-old man with non-HIV-associated recurrent Kaposi's sarcoma had previously undergone multiple surgeries on both his legs and had been treated with etoposide as systemic chemotherapy. After two cycles of TY21580 monotherapy (15 mg / kg), the target lesion in his left leg completely disappeared, and the tumor achieved partial response (PR; Table 5). TIFF2025529121000010.tif57170

[0176] Combination therapy results Interim results of the study are listed below.

[0177] General Observations Nine patients received TY21580 and toripalimab combination therapy (Tables 6 and 7). The median age was 59 years, 11% had received three or more lines of prior therapy, and none had received IO therapy. In the 6-mpk combination of TY21580 and toripalimab, two patients (2 / 3; Grade 3 fasciitis and Grade 3 diarrhea) developed DLTs. In the 3-mpk combination of TY21580 and toripalimab, one DLT (1 / 6; Grade 3 diarrhea) was observed, and five patients are currently undergoing treatment (2 to 5 cycles).

[0178] Tumor measurements were available for three patients; one patient with recurrent platinum-refractory HNSCC had a confirmed complete response (CR), and two patients had stable disease and a reduction in the total size of target lesions.

[0179] Based on the initial safety and efficacy results for the combination study, TY21580 (3 mg / kg, Q3W) combined with toripalimab (240 mg, Q3W) continuous administration demonstrated a manageable safety profile and promoted efficacy, including CR, supporting its further clinical development. TIFF2025529121000011.tif46170TIFF2025529121000012.tif59170

[0180] Subject 1 - Combination group A 65-year-old man with recurrent head and neck squamous cell carcinoma after comprehensive multimodality treatment consisting of surgery, radiotherapy, and chemotherapy showed a complete response (CR) after two cycles of treatment with a combination of TY21580 (3 mg / kg Q3W) and toripalimab (240 mg Q3W), with CR confirmed by the following tumor assessments (Table 8).

[0181] Subject 2 - combination group A 69-year-old woman was diagnosed with angiosarcoma, most recent metastatic disease documented in the right axillary node, multiple metastatic lesions in the liver (approximately 30) and spleen (approximately 20), extensive bone metastases, previously heavily treated, previous treatment included doxorubicin, paclitaxel, and Eribulin.

[0182] The patient was started on a combination of TY21580 (3 mg / kg Q3W) and toripalimab (240 mg Q3W), and the total size of the target lesions decreased significantly, decreasing by 25% at the second tumor assessment (Table 8). TIFF2025529121000013.tif75170

[0183] Example 2: PK comparison of TY21580 and ipilimumab (Ipi) supports 3 mg / kg Q3W and Q6W dosing in the combination treatment setting (with anti-PD-1 mAbs)

[0184] method TY21580 serum interim PK data were obtained and validated PK assays were used. Noncompartmental analysis (NCA, Phoenix® WinNonlin®) and population PK (popPK) analysis by Phoenix NLME™ (Phoenix WinNonlin V8.3, Certara) were used to analyze TY21580 interim PK data.

[0185] PK and Dosage Assessment Population PK modeling of TY21580 was performed. Figure 1 shows the observed individual PK values ​​for Cycle 1 of TY21580 after a 3 mg / kg dose and the model-predicted TY21580 population PK at steady state (repeated dosing at 3 mg / kg Q3W or Q6W) compared to the observed PK of ipilimumab at steady state (repeated dosing at 1 mg / kg). Based on published systemic PK and head-to-head comparisons of ipilimumab in vitro binding and functional data, TY21580 is expected to achieve greater receptor occupancy (RO) and target engagement (TE) with 3 mg / kg Q3W and Q6W dosing compared to the currently approved 1 mg / kg Q6W dosing of ipilimumab, currently approved for combination treatment with nivolumab for a number of cancer indications (see: https: / / packageinserts.bms.com / pi / pi_yervoy.pdf).

[0186] With Q6W dosing of 3 mg / kg TY21580, calculated tumor tissue RO (10-20% factor depletion of antibody in tumor compartment compared to CTLA-4, systemic PK) based on in vivo TY21580 PK and in vitro binding and CD80 / CD86 ligand blocking data was >90% at 7 days post-dose (RO is C max EC 95 ), and is expected to be >50% by week 6 post-dose. Dosing TY21580 Q3W results in greater PK accumulation compared to Q6W dosing, resulting in greater RO coverage at steady state. In contrast, tumor tissue RO calculated based on mean in vivo ipilimumab PK (1 mg / kg Q6W dosing, steady state) and ipilimumab in vitro binding / ligand inhibition data is C max This is expected to decrease to less than 90% at 6 weeks and to less than 50% approximately 3 weeks after administration (e.g., using the same antibody-tumor fractionation rate of 10-20%). Furthermore, non-compartmental analysis (NCA) showed that the AUC tau.ssThe C (area under the concentration-time curve during each dosing interval at steady state) of TY21580 3 mg / kg (Q6W or Q3W) was approximately twice as high as that of ipilimumab (1 mg / kg Q6W). max.ss (maximum drug concentration at steady state) is approximately three times higher than that of ipilimumab (1 mg / kg Q6W repeated doses).

[0187] Based on an integrated understanding of the mechanisms of action (MOA) of TY21580 and ipilimumab that drive clinical efficacy, the excellent clinical safety profile of TY21580 as monotherapy and in combination treatment settings (e.g., with anti-PD-1 mAbs) when combined with many approved cancer indications (e.g., ipilimumab administered at 1 mg / kg Q6W repeat doses or 3 mg / kg Q3W doses for the first four cycles), allows TY21580 to be administered significantly higher (e.g., 3X in terms of mg / kg) and more frequently / continuously, which can reach RO values ​​at the site of action (e.g., ≥90%) that can drive greater pharmacodynamic (PD) effects.

[0188] Taken together, this analysis supports that, based on integrated PK / PD evaluation, combining TY21580 3 mg / kg Q3W and / or Q6W continuous dosing with anti-PD-1 (or PD-L1) mAbs may result in greater therapeutic benefit compared with similar approved regimens (e.g., ipilimumab + nivolumab).

[0189] Example 3. Treatment of metastatic endometrial cancer with TY21580

[0190] A 44-year-old woman was diagnosed with endometrial carcinoma, microsatellite instability-high (MSI-H). The most recent documented metastatic disease was a right superior pulmonary lymph node metastasis (approximately 19 mm) and a left pulmonary subclavian lymph node metastasis (approximately 31 mm). She had previously received treatment with docetaxel, cisplatin, and an EZH1 / EZH2 inhibitor. The patient was initiated on monotherapy with TY21580 (10 mg / kg Q3W). After treatment, the sum of the target lesions significantly decreased in size at the first tumor assessment. As shown in Table 9, the best response was achieved at the third tumor assessment, with a 50% reduction based on the total target lesions at screening. TIFF2025529121000014.tif76170

[0191] Example 4. Treatment of metastatic clear cell renal cell carcinoma with TY21580

[0192] A 56-year-old man was diagnosed with renal clear cell carcinoma. His most recent metastatic disease included a right-middle lower lung metastasis (approximately 15 mm), a right middle lobe lung metastasis (approximately 16 mm), a right interlobar lymph node metastasis (approximately 22 mm), a kidney metastasis (approximately 47 mm), and a retrocaval lymph node metastasis (approximately 15 mm). He had previously been treated with sunitinib and subsequently with an investigational oral PD-L1 inhibitor. The patient was initiated on TY21580 (10 mg / kg Q3W) monotherapy. As shown in Table 10, after treatment with TY21580, the total size of the target lesions significantly decreased, reaching a 41% reduction at the third tumor assessment. TIFF2025529121000015.tif95170

[0193] Example 5. Treatment of metastatic HSNCC with a combination of TY21580 and toripalimab

[0194] A 64-year-old man was diagnosed with HPV-negative recurrent head and neck squamous cell carcinoma (HNSCC). The most recent documented metastatic disease was in the liver (approximately 30 nodes) and right submandibular (approximately 20 nodes), as well as lymph node metastases. Treatment to date included right cervical lymph node dissection followed by adjuvant radiation therapy (local therapy) and concurrent chemoradiotherapy with weekly cisplatin administration. The patient was initiated on a combination of TY21580 (3 mg / kg) and toripalimab 240 mg every 3 weeks. As shown in Table 11, the total size of the target lesions significantly decreased, and a durable complete response was observed since the initial tumor evaluation. TIFF2025529121000016.tif90170

[0195] Example 6. Treatment of metastatic colorectal cancer with a combination of TY21580 and toripalimab

[0196] A 50-year-old woman was diagnosed with microsatellite-stable (MSS) colorectal cancer. Her most recent documented metastatic disease included widespread lymph node involvement in the right para-aortic and common iliac lymph nodes (approximately 45 lymph nodes). She had previously received intensive treatment with anticancer therapies, including MFOLFOXIRI, bevacizumab, encorafenib, cetuximab, and TAS102. The patient was initiated on TY21580 3 mg / kg Q6W in combination with toripalimab 240 mg Q3W. As shown in Table 12, the total size of target lesions significantly decreased, and the initial tumor assessment demonstrated a partial response of 32%. TIFF2025529121000017.tif65170

[0197] Example 7. Evaluation of the immunogenicity of TY21580

[0198] The anti-drug antibody (ADA) assay for the TY21580 clinical trial was validated in a GLP laboratory in three stages: screening, confirmation, and titration. The ADA assay was used to evaluate the immunogenicity of TY21580 in 72 patients from clinical trials of TY21580 doses up to 15 mg / kg. Currently, among these 72 patients, only one patient from the clinical study up to 15 mg / kg showed a treatment-emergent ADA positivity (Table 13). The post-treatment positivity rate is 1.4%. Furthermore, based on graphical assessment (e.g., time vs. PK) and quantitative assessment evaluating the population average PK when ADA was negative and individual PK at specific time points when ADA was positive, there was no apparent impact of ADA on pharmacokinetics (PK). TIFF2025529121000018.tif58170

Claims

1. A pharmaceutical for use in the treatment of cancer in a human subject, comprising an effective amount of anti-CTLA4 antibody in combination with an effective amount of anti-PD-1 antibody, wherein the anti-CTLA4 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region of the antibody comprises HVR-H1, HVR-H2, and HVR-H3, the light chain variable region of the antibody comprises HVR-L1, HVR-L2, and HVR-L3, the HVR-H1 comprises an amino acid sequence according to the formula YSISSGYHWSWI (SEQ ID NO: 23), and the HVR-H2 comprises an amino acid sequence according to the formula LARIDWDDDKYYYSTSLKSR The pharmaceutical preparation comprises an amino acid sequence according to L (SEQ ID NO: 35), HVR-H3 comprises an amino acid sequence according to formula ARSYVYFDY (SEQ ID NO: 45), HVR-L1 comprises an amino acid sequence according to formula RASQSVRGRFLA (SEQ ID NO: 58), HVR-L2 comprises an amino acid sequence according to formula DASNRATGI (SEQ ID NO: 66), and HVR-L3 comprises an amino acid sequence according to formula YCQQSSSSWPPT (SEQ ID NO: 75), wherein the anti-CTLA4 antibody is administered once every three weeks or once every six weeks at a dose of approximately 2 mg / kg to approximately 5 mg / kg.

2. A pharmaceutical for use in the treatment of cancer in human subjects, comprising an effective amount of anti-PD-1 antibody in combination with an effective amount of anti-CTLA4 antibody, wherein the anti-CTLA4 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region of the antibody comprises HVR-H1, HVR-H2, and HVR-H3, the light chain variable region of the antibody comprises HVR-L1, HVR-L2, and HVR-L3, and the HVR-H1 comprises an amino acid sequence according to the formula YSISSGYHWSWI (SEQ ID NO: 23). HVR-H2 contains an amino acid sequence following the formula LARIDWDDDKYYYSTSLKSRL (SEQ ID NO: 35), HVR-H3 contains an amino acid sequence following the formula ARSYVYFDY (SEQ ID NO: 45), HVR-L1 contains an amino acid sequence following the formula RASQSVRGRFLA (SEQ ID NO: 58), HVR-L2 contains an amino acid sequence following the formula DASNRATGI (SEQ ID NO: 66), and HVR-L3 contains an amino acid sequence following the formula YCQQSSSSWPPT (SEQ ID NO: 75). The pharmaceutical product wherein the anti-CTLA4 antibody is administered once every three weeks or once every six weeks at a dose of approximately 2 mg / kg to approximately 5 mg / kg.

3. A pharmaceutical for use in the treatment of cancer in a human subject, comprising an effective amount of anti-CTLA4 antibody and an effective amount of anti-PD-1 antibody, wherein the anti-CTLA4 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region of the antibody comprises HVR-H1, HVR-H2, and HVR-H3, the light chain variable region of the antibody comprises HVR-L1, HVR-L2, and HVR-L3, the HVR-H1 comprises an amino acid sequence according to the formula YSISSGYHWSWI (SEQ ID NO: 23), and the HVR-H2 comprises an amino acid sequence according to the formula LARIDWDDDKYYYSTSLKSRL (part The pharmaceutical preparation comprises an amino acid sequence according to sequence number 35), HVR-H3 comprises an amino acid sequence according to formula ARSYVYFDY (SEQ ID NO: 45), HVR-L1 comprises an amino acid sequence according to formula RASQSVRGRFLA (SEQ ID NO: 58), HVR-L2 comprises an amino acid sequence according to formula DASNRATGI (SEQ ID NO: 66), and HVR-L3 comprises an amino acid sequence according to formula YCQQSSSSWPPT (SEQ ID NO: 75), wherein the anti-CTLA4 antibody is administered once every three weeks or once every six weeks at a dose of approximately 2 mg / kg to approximately 5 mg / kg.

4. A pharmaceutical for use in the treatment of cancer in human subjects, comprising an effective amount of anti-CTLA4 antibody and an effective amount of anti-PD-1 antibody administered in combination, wherein the anti-CTLA4 antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region of the antibody comprises HVR-H1, HVR-H2, and HVR-H3, the light chain variable region of the antibody comprises HVR-L1, HVR-L2, and HVR-L3, the HVR-H1 comprises an amino acid sequence according to the formula YSISSGYHWSWI (SEQ ID NO: 23), and the HVR-H2 comprises an amino acid sequence according to the formula LARIDWDDDKYYYSTSLKS The pharmaceutical product comprises an amino acid sequence according to RL (SEQ ID NO: 35), HVR-H3 comprises an amino acid sequence according to formula ARSYVYFDY (SEQ ID NO: 45), HVR-L1 comprises an amino acid sequence according to formula RASQSVRGRFLA (SEQ ID NO: 58), HVR-L2 comprises an amino acid sequence according to formula DASNRATGI (SEQ ID NO: 66), and HVR-L3 comprises an amino acid sequence according to formula YCQQSSSSWPPT (SEQ ID NO: 75), wherein the anti-CTLA4 antibody is administered once every three weeks or once every six weeks at a dose of approximately 2 mg / kg to approximately 5 mg / kg.

5. The pharmaceutical product according to any one of claims 1 to 4, wherein the anti-CTLA4 antibody is administered once every three weeks or once every six weeks at a dose of approximately 3 mg / kg to approximately 5 mg / kg, or once every three weeks or once every six weeks at a dose of approximately 3 mg / kg.

6. The pharmaceutical product according to any one of claims 1 to 4, wherein the cancer is resistant or refractory to prior treatment, and the prior treatment is an inhibitor of CTLA4, PD-1, or a PD-1 ligand, or ipilimumab.

7. The pharmaceutical product according to any one of claims 1 to 4, wherein the cancer is Kaposi's sarcoma, head and neck squamous cell carcinoma (HNSCC), angiosarcoma, pancreatic or ovarian cancer, or colorectal cancer.

8. The pharmaceutical product according to any one of claims 1 to 4, wherein the anti-PD-1 antibody is tripalimab.

9. The pharmaceutical product according to any one of claims 1 to 4, wherein the heavy chain variable region includes the amino acid sequence of SEQ ID NO: 87 and the light chain variable region includes the amino acid sequence of SEQ ID NO: 100, or the anti-CTLA4 antibody includes a heavy chain region including the amino acid sequence of SEQ ID NO: 125 or SEQ ID NO: 126 and a light chain region including the amino acid sequence of SEQ ID NO: 127.

Images